[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxYBN5HC9WHz2MKCVMLJINYL1c0VSmBmiPasQxWiT4uw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":83,"rows":90},"Amsterdam UMC, location VUmc",[4],299,false,67,18,100417,21,185,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Multiple Sclerosis",11,{"name":18,"count":19},"Breast Cancer",7,{"name":21,"count":19},"Coronary Artery Disease",{"name":23,"count":24},"Diabetes Mellitus, Type 2",6,{"name":26,"count":24},"Type 2 Diabetes",{"name":28,"count":24},"Colorectal Cancer",{"name":30,"count":24},"Obesity",{"name":32,"count":33},"Critical Illness",5,[35,40,44,49,54,59,64,68,73,78],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05216328","Prevention of Opioid-induced Constipation in Patients With Advanced Cancer","2025-12","Macrogol Only Product in Oral Dose Form",{"nctId":41,"briefTitle":42,"date":38,"intervention":43},"NCT06983054","DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes","ertugliflozine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06731361","Improved Prescribing for Older Nursing Home Patients","2025-12-01","Systematic multidisciplinary medication review + ACP",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06658522","Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)","2026-05-01","Sotatercept",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05415397","Treating Immuno-metabolic Depression With Anti-inflammatory Drugs","2026-07","Celecoxib 400mg",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05088785","Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer","2026-12","FES",{"nctId":65,"briefTitle":66,"date":62,"intervention":67},"NCT06687876","Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","Metformin",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT05834855","Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS","2027-05","Rituximab",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT05861505","COLLISION RELAPSE Trial","2027-05-01","Neoadjuvant systemic therapy",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06457789","Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer","2027-08","[18F]F-AraG PET imaging",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,117,139,157,177,222,247,265,288,314,340,365,390,408,426,449,470,488,508,535,560,586,634,675,701,725,752,770,794,812,842,860,878,896,914,940,958,985,1003,1021,1047,1075,1102,1120,1146,1171,1196,1214,1238,1263,1281,1307,1334,1352,1376,1394,1412,1441,1459,1477,1495,1513,1531,1555,1578,1603,1621,1648,1673,1699,1724,1749,1775,1793,1818,1844,1862,1889,1907,1936,1963,1981,1999,2022,2048,2073,2100,2118,2144,2168,2192,2217,2242,2267,2285,2309,2331,2356,2384,2402,2420,2447,2470,2494,2518,2543,2561,2597,2631,2656,2680,2704,2722,2785,2828,2859,2893,2922,2950,2984,3019,3044,3062,3091,3109,3127,3150,3175,3199,3217,3235,3253,3271,3289,3315,3333,3351,3375,3400,3418,3436,3460,3478,3502,3528,3546,3564,3589,3619,3637,3655,3673,3697,3715,3740,3758,3781,3799,3817,3841,3859],{"intervention":53,"totalTrials":92,"cells":93},1,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":115},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":52},[105],{"nctId":50,"briefTitle":51,"status":106,"phases":107,"primaryCompletion":52,"completion":52,"start":108,"enrollment":109,"conditions":110,"interventions":114},"RECRUITING",[88],"2025-05-14",20,[111,112,113],"Pulmonary Arterial Hypertension PAH","Pulmonary Arterial Hypertension WHO Group I","Pulmonary Arterial Hypertension",[53],{"trials":116,"activeCount":96},[],{"intervention":39,"totalTrials":92,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":137},{"trials":120,"activeCount":96},[],{"trials":122,"activeCount":96},[],{"trials":124,"activeCount":96},[],{"trials":126,"activeCount":96},[],{"trials":128,"activeCount":92,"soonestReadout":38},[129],{"nctId":36,"briefTitle":37,"status":106,"phases":130,"primaryCompletion":38,"completion":38,"start":131,"enrollment":132,"conditions":133,"interventions":135},[88],"2022-12-02",330,[134],"Constipation, Opioid-Induced",[39,136],"Magnesium hydroxide 724mg",{"trials":138,"activeCount":96},[],{"intervention":136,"totalTrials":92,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":155},{"trials":142,"activeCount":96},[],{"trials":144,"activeCount":96},[],{"trials":146,"activeCount":96},[],{"trials":148,"activeCount":96},[],{"trials":150,"activeCount":92,"soonestReadout":38},[151],{"nctId":36,"briefTitle":37,"status":106,"phases":152,"primaryCompletion":38,"completion":38,"start":131,"enrollment":132,"conditions":153,"interventions":154},[88],[134],[39,136],{"trials":156,"activeCount":96},[],{"intervention":43,"totalTrials":92,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":175},{"trials":160,"activeCount":96},[],{"trials":162,"activeCount":96},[],{"trials":164,"activeCount":96},[],{"trials":166,"activeCount":96},[],{"trials":168,"activeCount":92,"soonestReadout":38},[169],{"nctId":41,"briefTitle":42,"status":106,"phases":170,"primaryCompletion":38,"completion":38,"start":171,"enrollment":172,"conditions":173,"interventions":174},[88],"2023-07-25",34,[26],[43],{"trials":176,"activeCount":96},[],{"intervention":178,"totalTrials":179,"cells":180},"Pembrolizumab",2,{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":200,"PHASE4":218,"NA":220},{"trials":182,"activeCount":96},[],{"trials":184,"activeCount":96},[],{"trials":186,"activeCount":92,"soonestReadout":191},[187],{"nctId":188,"briefTitle":189,"status":106,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":198},"NCT06384560","Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)",[85,86],"2028-03","2024-09-23",66,[195,196,197],"Localized Pancreatic Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Resectable Pancreatic Adenocarcinoma",[178,199],"Folfirinox",{"trials":201,"activeCount":92,"soonestReadout":207},[202],{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":216},"NCT06923475","Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma","NOT_YET_RECRUITING",[86,87],"2028-11-06","2025-05-05",150,[211,212,213,214,215],"Extrahepatic Cholangiocarcinoma","Perihilar Cholangiocarcinoma","Distal Cholangiocarcinoma","Resectable","Borderline Resectable",[178,217],"Gemcitabine, Cisplatin",{"trials":219,"activeCount":96},[],{"trials":221,"activeCount":96},[],{"intervention":72,"totalTrials":92,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":243,"NA":245},{"trials":225,"activeCount":96},[],{"trials":227,"activeCount":96},[],{"trials":229,"activeCount":96},[],{"trials":231,"activeCount":92,"soonestReadout":71},[232],{"nctId":69,"briefTitle":70,"status":106,"phases":233,"primaryCompletion":71,"completion":71,"start":234,"enrollment":235,"conditions":236,"interventions":242},[87],"2023-04",200,[15,237,238,239,240,241],"Multiple Sclerosis, Relapsing-Remitting","Demyelinating Autoimmune Diseases, CNS","Autoimmune Diseases of the Nervous System","Nervous System Diseases","Demyelinating Diseases",[72],{"trials":244,"activeCount":96},[],{"trials":246,"activeCount":96},[],{"intervention":217,"totalTrials":92,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":261,"NA":263},{"trials":250,"activeCount":96},[],{"trials":252,"activeCount":96},[],{"trials":254,"activeCount":96},[],{"trials":256,"activeCount":92,"soonestReadout":207},[257],{"nctId":203,"briefTitle":204,"status":205,"phases":258,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":259,"interventions":260},[86,87],[211,212,213,214,215],[178,217],{"trials":262,"activeCount":96},[],{"trials":264,"activeCount":96},[],{"intervention":58,"totalTrials":92,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":284,"NA":286},{"trials":268,"activeCount":96},[],{"trials":270,"activeCount":96},[],{"trials":272,"activeCount":96},[],{"trials":274,"activeCount":92,"soonestReadout":57},[275],{"nctId":55,"briefTitle":56,"status":276,"phases":277,"primaryCompletion":57,"completion":57,"start":278,"enrollment":279,"conditions":280,"interventions":283},"ACTIVE_NOT_RECRUITING",[87],"2022-09-28",140,[281,282],"Depressive Disorder, Major","Inflammation",[58],{"trials":285,"activeCount":96},[],{"trials":287,"activeCount":96},[],{"intervention":289,"totalTrials":92,"cells":290},"repetitive transcranial magnetic stimulation",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":310,"NA":312},{"trials":292,"activeCount":96},[],{"trials":294,"activeCount":96},[],{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":92,"soonestReadout":303},[299],{"nctId":300,"briefTitle":301,"status":106,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":309},"NCT05331937","TMS for Exposure Therapy Resistant OCD",[87],"2027-12-01","2022-05-16",250,[307,308],"1 Hz Real rTMS to the Pre-SMA","1 Hz Sham rTMS to the Pre-SMA",[289],{"trials":311,"activeCount":96},[],{"trials":313,"activeCount":96},[],{"intervention":77,"totalTrials":92,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":320,"PHASE3":322,"PHASE4":336,"NA":338},{"trials":317,"activeCount":96},[],{"trials":319,"activeCount":96},[],{"trials":321,"activeCount":96},[],{"trials":323,"activeCount":92,"soonestReadout":76},[324],{"nctId":74,"briefTitle":75,"status":106,"phases":325,"primaryCompletion":76,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":335},[87],"2028-05-01","2023-04-24",360,[28,330,331,332,333,334],"Liver Metastases","Liver Metastasis Colon Cancer","Chemotherapy Effect","Surgery","Recurrence",[77],{"trials":337,"activeCount":96},[],{"trials":339,"activeCount":96},[],{"intervention":341,"totalTrials":92,"cells":342},"Iberdomide plus low-dose cyclophosphamide and dexamethasone",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":344,"activeCount":96},[],{"trials":346,"activeCount":96},[],{"trials":348,"activeCount":92,"soonestReadout":353},[349],{"nctId":350,"briefTitle":351,"status":276,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT04392037","Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone",[86],"2027-12","2021-02-17",60,[357],"Multiple Myeloma",[341],{"trials":360,"activeCount":96},[],{"trials":362,"activeCount":96},[],{"trials":364,"activeCount":96},[],{"intervention":366,"totalTrials":92,"cells":367},"Group 1 - Intradermal ipilimumab",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":369,"activeCount":96},[],{"trials":371,"activeCount":96},[],{"trials":373,"activeCount":92,"soonestReadout":378},[374],{"nctId":375,"briefTitle":376,"status":205,"phases":377,"primaryCompletion":378,"completion":379,"start":57,"enrollment":9,"conditions":380,"interventions":382},"NCT07615881","Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma",[85,86],"2028-07","2029-07",[381],"Melanoma (Skin Cancer)",[366,383],"Group 2 - Conventional treatment",{"trials":385,"activeCount":96},[],{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":96},[],{"intervention":383,"totalTrials":92,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":393,"activeCount":96},[],{"trials":395,"activeCount":96},[],{"trials":397,"activeCount":92,"soonestReadout":378},[398],{"nctId":375,"briefTitle":376,"status":205,"phases":399,"primaryCompletion":378,"completion":379,"start":57,"enrollment":9,"conditions":400,"interventions":401},[85,86],[381],[366,383],{"trials":403,"activeCount":96},[],{"trials":405,"activeCount":96},[],{"trials":407,"activeCount":96},[],{"intervention":199,"totalTrials":92,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":411,"activeCount":96},[],{"trials":413,"activeCount":96},[],{"trials":415,"activeCount":92,"soonestReadout":191},[416],{"nctId":188,"briefTitle":189,"status":106,"phases":417,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":418,"interventions":419},[85,86],[195,196,197],[178,199],{"trials":421,"activeCount":96},[],{"trials":423,"activeCount":96},[],{"trials":425,"activeCount":96},[],{"intervention":67,"totalTrials":92,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":443,"PHASE4":445,"NA":447},{"trials":429,"activeCount":96},[],{"trials":431,"activeCount":96},[],{"trials":433,"activeCount":92,"soonestReadout":62},[434],{"nctId":65,"briefTitle":66,"status":106,"phases":435,"primaryCompletion":62,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":442},[86],"2030-12","2025-03-09",14,[440,441],"Oesophageal Adenocarcinoma","Tumor Microenvironment",[67],{"trials":444,"activeCount":96},[],{"trials":446,"activeCount":96},[],{"trials":448,"activeCount":96},[],{"intervention":82,"totalTrials":92,"cells":450},{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":461},{"trials":452,"activeCount":96},[],{"trials":454,"activeCount":96},[],{"trials":456,"activeCount":96},[],{"trials":458,"activeCount":96},[],{"trials":460,"activeCount":96},[],{"trials":462,"activeCount":92,"soonestReadout":81},[463],{"nctId":79,"briefTitle":80,"status":106,"phases":464,"primaryCompletion":81,"completion":378,"start":465,"enrollment":172,"conditions":466,"interventions":468},[89],"2024-12-01",[467],"NSCLC",[82,469],"[89Zr]Zr-Df-Crefmirlimab PET imaging",{"intervention":469,"totalTrials":92,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":473,"activeCount":96},[],{"trials":475,"activeCount":96},[],{"trials":477,"activeCount":96},[],{"trials":479,"activeCount":96},[],{"trials":481,"activeCount":96},[],{"trials":483,"activeCount":92,"soonestReadout":81},[484],{"nctId":79,"briefTitle":80,"status":106,"phases":485,"primaryCompletion":81,"completion":378,"start":465,"enrollment":172,"conditions":486,"interventions":487},[89],[467],[82,469],{"intervention":63,"totalTrials":92,"cells":489},{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":498,"NA":500},{"trials":491,"activeCount":96},[],{"trials":493,"activeCount":96},[],{"trials":495,"activeCount":96},[],{"trials":497,"activeCount":96},[],{"trials":499,"activeCount":96},[],{"trials":501,"activeCount":92,"soonestReadout":62},[502],{"nctId":60,"briefTitle":61,"status":276,"phases":503,"primaryCompletion":62,"completion":62,"start":504,"enrollment":505,"conditions":506,"interventions":507},[89],"2021-10-11",15,[18],[63],{"intervention":48,"totalTrials":92,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":511,"activeCount":96},[],{"trials":513,"activeCount":96},[],{"trials":515,"activeCount":96},[],{"trials":517,"activeCount":96},[],{"trials":519,"activeCount":96},[],{"trials":521,"activeCount":92,"soonestReadout":47},[522],{"nctId":45,"briefTitle":46,"status":106,"phases":523,"primaryCompletion":47,"completion":47,"start":524,"enrollment":525,"conditions":526,"interventions":534},[89],"2024-09-10",450,[527,528,529,530,531,532,533],"Nursing Home Residents","Older People","Prescribing","Advance Care Planning","Medication Reviews","Decision Making","Prescribing Practices",[48],{"intervention":536,"totalTrials":92,"cells":537},"Intrathecal Baclofen Pump",{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":539,"activeCount":96},[],{"trials":541,"activeCount":96},[],{"trials":543,"activeCount":96},[],{"trials":545,"activeCount":96},[],{"trials":547,"activeCount":96},[],{"trials":549,"activeCount":92,"soonestReadout":303},[550],{"nctId":551,"briefTitle":552,"status":205,"phases":553,"primaryCompletion":303,"completion":303,"start":554,"enrollment":555,"conditions":556,"interventions":559},"NCT05817409","Predictive Factors for Succes of ITB in CP",[],"2023-06-01",75,[557,558],"Cerebral Palsy","Intrathecal Baclofen",[536],{"intervention":561,"totalTrials":92,"cells":562},"Inotropes",{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":564,"activeCount":96},[],{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":96},[],{"trials":570,"activeCount":96},[],{"trials":572,"activeCount":96},[],{"trials":574,"activeCount":92,"soonestReadout":579},[575],{"nctId":576,"briefTitle":577,"status":205,"phases":578,"primaryCompletion":579,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT05064202","Unloading in Heart Failure Cardiogenic Shock",[89],"2027-10-01","2028-07-01","2023-10-01",456,[584],"Cardiogenic Shock",[561],{"intervention":587,"totalTrials":588,"cells":589},"Empagliflozin 10 MG",3,{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":607,"PHASE4":609,"NA":632},{"trials":591,"activeCount":96},[],{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":96},[596],{"nctId":597,"briefTitle":598,"status":599,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":606},"NCT05493371","Empagliflozin in Pulmonary Arterial Hypertension","COMPLETED",[86],"2024-11-01","2023-03-01",8,[605],"Idiopathic Pulmonary Arterial Hypertension",[587],{"trials":608,"activeCount":96},[],{"trials":610,"activeCount":96},[611,621],{"nctId":612,"briefTitle":613,"status":614,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":96,"conditions":618,"interventions":620},"NCT04243850","REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations","WITHDRAWN",[88],"2022-03-01","2020-07-01",[23,619],"Chronic Kidney Diseases",[587],{"nctId":622,"briefTitle":623,"status":599,"phases":624,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT04238702","Renohemodynamic Effects of Combined empagliflOzin and LosARtan",[88],"2021-09-27","2020-11-04",24,[23,629],"Diabetic Kidney Disease",[587,631],"Losartan 50Mg Tab",{"trials":633,"activeCount":96},[],{"intervention":635,"totalTrials":179,"cells":636},"Ertugliflozin 15 mg",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":673},{"trials":638,"activeCount":96},[],{"trials":640,"activeCount":96},[],{"trials":642,"activeCount":96},[],{"trials":644,"activeCount":96},[],{"trials":646,"activeCount":96},[647,658],{"nctId":648,"briefTitle":649,"status":599,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":657},"NCT05727579","DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study",[88],"2025-11-30","2023-07-03",41,[655,629,656],"Diabetes Mellitus","Hypertension",[635],{"nctId":659,"briefTitle":660,"status":599,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":672},"NCT04027530","Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.",[88],"2023-01-09","2020-12-10",40,[666,629,667,668,669,670,671],"Type 2 Diabetes Mellitus","Diabetic Nephropathy","Renal Hypoxia","Renoprotection","SGLT2 Inhibitor","Ertugliflozin",[635],{"trials":674,"activeCount":96},[],{"intervention":676,"totalTrials":92,"cells":677},"Varenicline",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":686,"NA":699},{"trials":679,"activeCount":96},[],{"trials":681,"activeCount":96},[],{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[688],{"nctId":689,"briefTitle":690,"status":691,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":698},"NCT02473562","Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease","TERMINATED",[88],"2018-01","2013-05",22,[697],"Parkinson's Disease",[676],{"trials":700,"activeCount":96},[],{"intervention":702,"totalTrials":92,"cells":703},"ERA and PDE-5I",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":712,"NA":723},{"trials":705,"activeCount":96},[],{"trials":707,"activeCount":96},[],{"trials":709,"activeCount":96},[],{"trials":711,"activeCount":96},[],{"trials":713,"activeCount":96},[714],{"nctId":715,"briefTitle":716,"status":717,"phases":718,"primaryCompletion":719,"completion":719,"start":694,"enrollment":720,"conditions":721,"interventions":722},"NCT03236818","Goal Oriented Strategy to Preserve Ejection Fraction Trial","UNKNOWN",[88],"2017-09",30,[113],[702],{"trials":724,"activeCount":96},[],{"intervention":726,"totalTrials":92,"cells":727},"GnRHa",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":750},{"trials":729,"activeCount":96},[],{"trials":731,"activeCount":96},[],{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":96},[738],{"nctId":739,"briefTitle":740,"status":717,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":746,"interventions":748},"NCT02288130","Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy",[88],"2017-07","2017-11","2014-12",100,[747],"Fibroids",[726,749],"Ulipristal",{"trials":751,"activeCount":96},[],{"intervention":749,"totalTrials":92,"cells":753},{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":768},{"trials":755,"activeCount":96},[],{"trials":757,"activeCount":96},[],{"trials":759,"activeCount":96},[],{"trials":761,"activeCount":96},[],{"trials":763,"activeCount":96},[764],{"nctId":739,"briefTitle":740,"status":717,"phases":765,"primaryCompletion":742,"completion":743,"start":744,"enrollment":745,"conditions":766,"interventions":767},[88],[747],[726,749],{"trials":769,"activeCount":96},[],{"intervention":771,"totalTrials":92,"cells":772},"atrorvastatin 10mg",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":792},{"trials":774,"activeCount":96},[],{"trials":776,"activeCount":96},[],{"trials":778,"activeCount":96},[],{"trials":780,"activeCount":96},[],{"trials":782,"activeCount":96},[783],{"nctId":784,"briefTitle":785,"status":717,"phases":786,"primaryCompletion":787,"completion":787,"start":788,"enrollment":355,"conditions":789,"interventions":790},"NCT00404599","Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin.",[88],"2009-07","2007-02",[655,656],[771,791],"simvastatin 40mg",{"trials":793,"activeCount":96},[],{"intervention":791,"totalTrials":92,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":810},{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":96},[806],{"nctId":784,"briefTitle":785,"status":717,"phases":807,"primaryCompletion":787,"completion":787,"start":788,"enrollment":355,"conditions":808,"interventions":809},[88],[655,656],[771,791],{"trials":811,"activeCount":96},[],{"intervention":813,"totalTrials":92,"cells":814},"Pomalidomide 4 mg every day in cycle 1",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":840},{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":96},[],{"trials":824,"activeCount":96},[825],{"nctId":826,"briefTitle":827,"status":599,"phases":828,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":835},"NCT05555329","Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study",[88],"2024-02-14","2022-12-01",12,[833,357,834],"Multiple Myeloma in Relapse","Multiple Myeloma, Refractory",[813,836,837,838,839],"Pomalidomide 4 mg every other day in cycle 2","Pomalidomide 2 mg every day in cycle 2","Pomalidomide 2 mg every day in cycle 3","Pomalidomide 4 mg every other day in cycle 3",{"trials":841,"activeCount":96},[],{"intervention":836,"totalTrials":92,"cells":843},{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":848,"PHASE3":850,"PHASE4":852,"NA":858},{"trials":845,"activeCount":96},[],{"trials":847,"activeCount":96},[],{"trials":849,"activeCount":96},[],{"trials":851,"activeCount":96},[],{"trials":853,"activeCount":96},[854],{"nctId":826,"briefTitle":827,"status":599,"phases":855,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":856,"interventions":857},[88],[833,357,834],[813,836,837,838,839],{"trials":859,"activeCount":96},[],{"intervention":837,"totalTrials":92,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":876},{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[],{"trials":867,"activeCount":96},[],{"trials":869,"activeCount":96},[],{"trials":871,"activeCount":96},[872],{"nctId":826,"briefTitle":827,"status":599,"phases":873,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":874,"interventions":875},[88],[833,357,834],[813,836,837,838,839],{"trials":877,"activeCount":96},[],{"intervention":838,"totalTrials":92,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":894},{"trials":881,"activeCount":96},[],{"trials":883,"activeCount":96},[],{"trials":885,"activeCount":96},[],{"trials":887,"activeCount":96},[],{"trials":889,"activeCount":96},[890],{"nctId":826,"briefTitle":827,"status":599,"phases":891,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":892,"interventions":893},[88],[833,357,834],[813,836,837,838,839],{"trials":895,"activeCount":96},[],{"intervention":839,"totalTrials":92,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":904,"PHASE4":906,"NA":912},{"trials":899,"activeCount":96},[],{"trials":901,"activeCount":96},[],{"trials":903,"activeCount":96},[],{"trials":905,"activeCount":96},[],{"trials":907,"activeCount":96},[908],{"nctId":826,"briefTitle":827,"status":599,"phases":909,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":910,"interventions":911},[88],[833,357,834],[813,836,837,838,839],{"trials":913,"activeCount":96},[],{"intervention":915,"totalTrials":92,"cells":916},"Personalized extended interval dosing of natalizumab",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":938},{"trials":918,"activeCount":96},[],{"trials":920,"activeCount":96},[],{"trials":922,"activeCount":96},[],{"trials":924,"activeCount":96},[],{"trials":926,"activeCount":96},[927],{"nctId":928,"briefTitle":929,"status":717,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":934,"interventions":936},"NCT04225312","Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis",[88],"2025-03-01","2020-02-03",300,[935],"Relapsing Remitting Multiple Sclerosis",[915,937],"Standard interval dosing",{"trials":939,"activeCount":96},[],{"intervention":937,"totalTrials":92,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":956},{"trials":943,"activeCount":96},[],{"trials":945,"activeCount":96},[],{"trials":947,"activeCount":96},[],{"trials":949,"activeCount":96},[],{"trials":951,"activeCount":96},[952],{"nctId":928,"briefTitle":929,"status":717,"phases":953,"primaryCompletion":931,"completion":931,"start":932,"enrollment":933,"conditions":954,"interventions":955},[88],[935],[915,937],{"trials":957,"activeCount":96},[],{"intervention":959,"totalTrials":92,"cells":960},"Empagliflozin 25 MG",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":983},{"trials":962,"activeCount":96},[],{"trials":964,"activeCount":96},[],{"trials":966,"activeCount":96},[],{"trials":968,"activeCount":96},[],{"trials":970,"activeCount":96},[971],{"nctId":972,"briefTitle":973,"status":599,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT05210517","SGLT2 Inhibition: Uric Acid Excretion Study",[88],"2021-06-08","2021-09-01","2020-10-01",10,[26],[959,981,982],"Benzbromaron","Empagliflozin 25 MG + benzbromarone 100 mg",{"trials":984,"activeCount":96},[],{"intervention":981,"totalTrials":92,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1001},{"trials":988,"activeCount":96},[],{"trials":990,"activeCount":96},[],{"trials":992,"activeCount":96},[],{"trials":994,"activeCount":96},[],{"trials":996,"activeCount":96},[997],{"nctId":972,"briefTitle":973,"status":599,"phases":998,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":999,"interventions":1000},[88],[26],[959,981,982],{"trials":1002,"activeCount":96},[],{"intervention":982,"totalTrials":92,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1009,"PHASE3":1011,"PHASE4":1013,"NA":1019},{"trials":1006,"activeCount":96},[],{"trials":1008,"activeCount":96},[],{"trials":1010,"activeCount":96},[],{"trials":1012,"activeCount":96},[],{"trials":1014,"activeCount":96},[1015],{"nctId":972,"briefTitle":973,"status":599,"phases":1016,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":1017,"interventions":1018},[88],[26],[959,981,982],{"trials":1020,"activeCount":96},[],{"intervention":1022,"totalTrials":92,"cells":1023},"Dapagliflozin 10mg",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1045},{"trials":1025,"activeCount":96},[],{"trials":1027,"activeCount":96},[],{"trials":1029,"activeCount":96},[],{"trials":1031,"activeCount":96},[],{"trials":1033,"activeCount":96},[1034],{"nctId":1035,"briefTitle":1036,"status":599,"phases":1037,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":1042,"interventions":1043},"NCT03361098","DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2",[88],"2019-11-25","2020-03-25","2017-09-18",65,[666,30],[1022,1044],"Exenatide",{"trials":1046,"activeCount":96},[],{"intervention":1048,"totalTrials":92,"cells":1049},"Change in daily dosage of Growth Hormone",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1073},{"trials":1051,"activeCount":96},[],{"trials":1053,"activeCount":96},[],{"trials":1055,"activeCount":96},[],{"trials":1057,"activeCount":96},[],{"trials":1059,"activeCount":96},[1060],{"nctId":1061,"briefTitle":1062,"status":599,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":694,"enrollment":1065,"conditions":1066,"interventions":1072},"NCT01877512","GH and Cardiovascular Risk Factors",[88],"2014-04",32,[1067,1068,1069,1070,1071],"Growth Hormone Deficiency","Cardiovascular Diseases","Metabolic Syndrome","Cognition","Physical Activity",[1048],{"trials":1074,"activeCount":96},[],{"intervention":1076,"totalTrials":92,"cells":1077},"Lopinavir\u002Fritonavir + zidovudine + lamivudine",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1100},{"trials":1079,"activeCount":96},[],{"trials":1081,"activeCount":96},[],{"trials":1083,"activeCount":96},[],{"trials":1085,"activeCount":96},[],{"trials":1087,"activeCount":96},[1088],{"nctId":1089,"briefTitle":1090,"status":717,"phases":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1098},"NCT00122226","MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)",[88],"2008-07","2003-01",50,[1096,1097],"HIV Infections","HIV-Associated Lipodystrophy Syndrome",[1076,1099],"Lopinavir\u002Fritonavir + nevirapine",{"trials":1101,"activeCount":96},[],{"intervention":1099,"totalTrials":92,"cells":1103},{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1110,"PHASE4":1112,"NA":1118},{"trials":1105,"activeCount":96},[],{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[],{"trials":1111,"activeCount":96},[],{"trials":1113,"activeCount":96},[1114],{"nctId":1089,"briefTitle":1090,"status":717,"phases":1115,"completion":1092,"start":1093,"enrollment":1094,"conditions":1116,"interventions":1117},[88],[1096,1097],[1076,1099],{"trials":1119,"activeCount":96},[],{"intervention":1121,"totalTrials":92,"cells":1122},"Oxygen",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1131,"NA":1144},{"trials":1124,"activeCount":96},[],{"trials":1126,"activeCount":96},[],{"trials":1128,"activeCount":96},[],{"trials":1130,"activeCount":96},[],{"trials":1132,"activeCount":96},[1133],{"nctId":1134,"briefTitle":1135,"status":599,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1143},"NCT02321072","Optimal Oxygenation in the Intensive Care Unit",[88],"2019-01","2019-05","2015-02",400,[1142],"Systemic Inflammatory Response Syndrome",[1121],{"trials":1145,"activeCount":96},[],{"intervention":1147,"totalTrials":92,"cells":1148},"Lipiodol UltraFluid",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1169},{"trials":1150,"activeCount":96},[],{"trials":1152,"activeCount":96},[],{"trials":1154,"activeCount":96},[],{"trials":1156,"activeCount":96},[],{"trials":1158,"activeCount":96},[1159],{"nctId":1160,"briefTitle":1161,"status":717,"phases":1162,"primaryCompletion":47,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT05608590","What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish",[88],"2026-01-01","2019-08-22",554,[1167],"Female Infertility",[1147],{"trials":1170,"activeCount":96},[],{"intervention":1172,"totalTrials":92,"cells":1173},"pravastatin",{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1180,"PHASE4":1182,"NA":1194},{"trials":1175,"activeCount":96},[],{"trials":1177,"activeCount":96},[],{"trials":1179,"activeCount":96},[],{"trials":1181,"activeCount":96},[],{"trials":1183,"activeCount":96},[1184],{"nctId":1185,"briefTitle":1186,"status":691,"phases":1187,"completion":1188,"start":1189,"enrollment":745,"conditions":1190,"interventions":1192},"NCT00384618","Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study",[88],"2005-08","2001-05",[1191],"Chronic Kidney Disease",[1172,1193],"vitamin E",{"trials":1195,"activeCount":96},[],{"intervention":1193,"totalTrials":92,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1212},{"trials":1199,"activeCount":96},[],{"trials":1201,"activeCount":96},[],{"trials":1203,"activeCount":96},[],{"trials":1205,"activeCount":96},[],{"trials":1207,"activeCount":96},[1208],{"nctId":1185,"briefTitle":1186,"status":691,"phases":1209,"completion":1188,"start":1189,"enrollment":745,"conditions":1210,"interventions":1211},[88],[1191],[1172,1193],{"trials":1213,"activeCount":96},[],{"intervention":1215,"totalTrials":92,"cells":1216},"Rivastigmine",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1236},{"trials":1218,"activeCount":96},[],{"trials":1220,"activeCount":96},[],{"trials":1222,"activeCount":96},[],{"trials":1224,"activeCount":96},[],{"trials":1226,"activeCount":96},[1227],{"nctId":1228,"briefTitle":1229,"status":691,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1235},"NCT01856738","Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease",[88],"2018-09","2013-11",91,[697],[1215],{"trials":1237,"activeCount":96},[],{"intervention":1239,"totalTrials":92,"cells":1240},"Lixisenatide",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1261},{"trials":1242,"activeCount":96},[],{"trials":1244,"activeCount":96},[],{"trials":1246,"activeCount":96},[],{"trials":1248,"activeCount":96},[],{"trials":1250,"activeCount":96},[1251],{"nctId":1252,"briefTitle":1253,"status":599,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":664,"conditions":1257,"interventions":1259},"NCT02276196","Effect of LIXIsenatide on the Renal System",[88],"2016-04","2014-09",[629,667,655,1258],"Glucagon-Like Peptide 1",[1239,1260],"Insulin glulisine",{"trials":1262,"activeCount":96},[],{"intervention":1260,"totalTrials":92,"cells":1264},{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1279},{"trials":1266,"activeCount":96},[],{"trials":1268,"activeCount":96},[],{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[],{"trials":1274,"activeCount":96},[1275],{"nctId":1252,"briefTitle":1253,"status":599,"phases":1276,"primaryCompletion":1255,"completion":1255,"start":1256,"enrollment":664,"conditions":1277,"interventions":1278},[88],[629,667,655,1258],[1239,1260],{"trials":1280,"activeCount":96},[],{"intervention":1282,"totalTrials":92,"cells":1283},"Insulin glargine",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1305},{"trials":1285,"activeCount":96},[],{"trials":1287,"activeCount":96},[],{"trials":1289,"activeCount":96},[],{"trials":1291,"activeCount":96},[],{"trials":1293,"activeCount":96},[1294],{"nctId":1295,"briefTitle":1296,"status":599,"phases":1297,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":1301,"interventions":1303},"NCT00766857","Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure",[88],"2012-12","2009-05",27,[666,1302],"Congestive Heart Failure",[1304,1282],"exenatide",{"trials":1306,"activeCount":96},[],{"intervention":1308,"totalTrials":92,"cells":1309},"Ticagrelor",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1332},{"trials":1311,"activeCount":96},[],{"trials":1313,"activeCount":96},[],{"trials":1315,"activeCount":96},[],{"trials":1317,"activeCount":96},[],{"trials":1319,"activeCount":96},[1320],{"nctId":1321,"briefTitle":1322,"status":717,"phases":1323,"primaryCompletion":1324,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1330},"NCT02422888","Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor",[88],"2017-10","2019-10","2015-05",110,[1329],"Myocardial Infarction",[1308,1331],"Prasugrel",{"trials":1333,"activeCount":96},[],{"intervention":1331,"totalTrials":92,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1350},{"trials":1337,"activeCount":96},[],{"trials":1339,"activeCount":96},[],{"trials":1341,"activeCount":96},[],{"trials":1343,"activeCount":96},[],{"trials":1345,"activeCount":96},[1346],{"nctId":1321,"briefTitle":1322,"status":717,"phases":1347,"primaryCompletion":1324,"completion":1325,"start":1326,"enrollment":1327,"conditions":1348,"interventions":1349},[88],[1329],[1308,1331],{"trials":1351,"activeCount":96},[],{"intervention":1353,"totalTrials":92,"cells":1354},"Linagliptin 5 mg QD",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1374},{"trials":1356,"activeCount":96},[],{"trials":1358,"activeCount":96},[],{"trials":1360,"activeCount":96},[],{"trials":1362,"activeCount":96},[],{"trials":1364,"activeCount":96},[1365],{"nctId":1366,"briefTitle":1367,"status":599,"phases":1368,"primaryCompletion":1255,"completion":1255,"start":1369,"enrollment":1370,"conditions":1371,"interventions":1372},"NCT02106104","Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes",[88],"2014-03",48,[26],[1353,1373],"Glimepiride 1 mg QD",{"trials":1375,"activeCount":96},[],{"intervention":1373,"totalTrials":92,"cells":1377},{"EARLY_PHASE1":1378,"PHASE1":1380,"PHASE2":1382,"PHASE3":1384,"PHASE4":1386,"NA":1392},{"trials":1379,"activeCount":96},[],{"trials":1381,"activeCount":96},[],{"trials":1383,"activeCount":96},[],{"trials":1385,"activeCount":96},[],{"trials":1387,"activeCount":96},[1388],{"nctId":1366,"briefTitle":1367,"status":599,"phases":1389,"primaryCompletion":1255,"completion":1255,"start":1369,"enrollment":1370,"conditions":1390,"interventions":1391},[88],[26],[1353,1373],{"trials":1393,"activeCount":96},[],{"intervention":631,"totalTrials":92,"cells":1395},{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1404,"NA":1410},{"trials":1397,"activeCount":96},[],{"trials":1399,"activeCount":96},[],{"trials":1401,"activeCount":96},[],{"trials":1403,"activeCount":96},[],{"trials":1405,"activeCount":96},[1406],{"nctId":622,"briefTitle":623,"status":599,"phases":1407,"primaryCompletion":625,"completion":625,"start":626,"enrollment":627,"conditions":1408,"interventions":1409},[88],[23,629],[587,631],{"trials":1411,"activeCount":96},[],{"intervention":1413,"totalTrials":92,"cells":1414},"Liraglutide",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1439},{"trials":1416,"activeCount":96},[],{"trials":1418,"activeCount":96},[],{"trials":1420,"activeCount":96},[],{"trials":1422,"activeCount":96},[],{"trials":1424,"activeCount":96},[1425],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1428,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1433},"NCT01744236","SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies",[88],"2015-08","2013-04",70,[26],[1413,1434,1044,1435,1436,1437,1438],"Sitagliptin","Liraglutide placebo","Sitagliptin placebo","Exenatide placebo","L-NMMA",{"trials":1440,"activeCount":96},[],{"intervention":1434,"totalTrials":92,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1457},{"trials":1444,"activeCount":96},[],{"trials":1446,"activeCount":96},[],{"trials":1448,"activeCount":96},[],{"trials":1450,"activeCount":96},[],{"trials":1452,"activeCount":96},[1453],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1454,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1455,"interventions":1456},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":1458,"activeCount":96},[],{"intervention":1435,"totalTrials":92,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1475},{"trials":1462,"activeCount":96},[],{"trials":1464,"activeCount":96},[],{"trials":1466,"activeCount":96},[],{"trials":1468,"activeCount":96},[],{"trials":1470,"activeCount":96},[1471],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1472,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1473,"interventions":1474},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":1476,"activeCount":96},[],{"intervention":1436,"totalTrials":92,"cells":1478},{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1485,"PHASE4":1487,"NA":1493},{"trials":1480,"activeCount":96},[],{"trials":1482,"activeCount":96},[],{"trials":1484,"activeCount":96},[],{"trials":1486,"activeCount":96},[],{"trials":1488,"activeCount":96},[1489],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1490,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1491,"interventions":1492},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":1494,"activeCount":96},[],{"intervention":1437,"totalTrials":92,"cells":1496},{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1503,"PHASE4":1505,"NA":1511},{"trials":1498,"activeCount":96},[],{"trials":1500,"activeCount":96},[],{"trials":1502,"activeCount":96},[],{"trials":1504,"activeCount":96},[],{"trials":1506,"activeCount":96},[1507],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1508,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1509,"interventions":1510},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":1512,"activeCount":96},[],{"intervention":1438,"totalTrials":92,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1529},{"trials":1516,"activeCount":96},[],{"trials":1518,"activeCount":96},[],{"trials":1520,"activeCount":96},[],{"trials":1522,"activeCount":96},[],{"trials":1524,"activeCount":96},[1525],{"nctId":1426,"briefTitle":1427,"status":599,"phases":1526,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":1527,"interventions":1528},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":1530,"activeCount":96},[],{"intervention":1532,"totalTrials":92,"cells":1533},"Rocuronium Bromide",{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1542,"NA":1553},{"trials":1535,"activeCount":96},[],{"trials":1537,"activeCount":96},[],{"trials":1539,"activeCount":96},[],{"trials":1541,"activeCount":96},[],{"trials":1543,"activeCount":96},[1544],{"nctId":1545,"briefTitle":1546,"status":717,"phases":1547,"primaryCompletion":1548,"completion":1548,"start":1549,"enrollment":720,"conditions":1550,"interventions":1552},"NCT03646266","Partial Neuromuscular Blockade for Lung Protective Mechanical Ventilation",[88],"2020-12-31","2018-08-15",[1551],"Respiratory Insufficiency",[1532],{"trials":1554,"activeCount":96},[],{"intervention":1556,"totalTrials":92,"cells":1557},"Ferricarboxymaltose",{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1576},{"trials":1559,"activeCount":96},[],{"trials":1561,"activeCount":96},[],{"trials":1563,"activeCount":96},[],{"trials":1565,"activeCount":96},[],{"trials":1567,"activeCount":96},[1568],{"nctId":1569,"briefTitle":1570,"status":717,"phases":1571,"primaryCompletion":1298,"completion":1572,"start":1573,"enrollment":720,"conditions":1574,"interventions":1575},"NCT01288651","Iron Deficiency In Pulmonary Hypertension",[88],"2013-01","2011-01",[605],[1556],{"trials":1577,"activeCount":96},[],{"intervention":1579,"totalTrials":92,"cells":1580},"Dapagliflozin",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1601},{"trials":1582,"activeCount":96},[],{"trials":1584,"activeCount":96},[],{"trials":1586,"activeCount":96},[],{"trials":1588,"activeCount":96},[],{"trials":1590,"activeCount":96},[1591],{"nctId":1592,"briefTitle":1593,"status":599,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":831,"conditions":1597,"interventions":1599},"NCT03074630","Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)",[88],"2018-04","2016-05",[23,1598],"Hypercholesterolemia",[1579,1600],"Rosuvastatin",{"trials":1602,"activeCount":96},[],{"intervention":1600,"totalTrials":92,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1611,"PHASE4":1613,"NA":1619},{"trials":1606,"activeCount":96},[],{"trials":1608,"activeCount":96},[],{"trials":1610,"activeCount":96},[],{"trials":1612,"activeCount":96},[],{"trials":1614,"activeCount":96},[1615],{"nctId":1592,"briefTitle":1593,"status":599,"phases":1616,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":831,"conditions":1617,"interventions":1618},[88],[23,1598],[1579,1600],{"trials":1620,"activeCount":96},[],{"intervention":1622,"totalTrials":92,"cells":1623},"Ascorbic Acid",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1632,"NA":1646},{"trials":1625,"activeCount":96},[],{"trials":1627,"activeCount":96},[],{"trials":1629,"activeCount":96},[],{"trials":1631,"activeCount":96},[],{"trials":1633,"activeCount":96},[1634],{"nctId":1635,"briefTitle":1636,"status":599,"phases":1637,"primaryCompletion":1638,"completion":1639,"start":1640,"enrollment":109,"conditions":1641,"interventions":1645},"NCT02455180","Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients",[88],"2016-10","2016-11","2015-03",[1642,1643,1142,1644],"Multiple Organ Failure","Sepsis","Trauma",[1622],{"trials":1647,"activeCount":96},[],{"intervention":1649,"totalTrials":92,"cells":1650},"Discontinuation of imipenem-cilastatin or meropenem",{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1671},{"trials":1652,"activeCount":96},[],{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[],{"trials":1658,"activeCount":96},[],{"trials":1660,"activeCount":96},[1661],{"nctId":1662,"briefTitle":1663,"status":599,"phases":1664,"primaryCompletion":1665,"completion":1665,"start":744,"enrollment":1666,"conditions":1667,"interventions":1670},"NCT02149329","Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO",[88],"2019-08-05",276,[1668,1669],"Febrile Neutropenia","Hematological Malignancy",[1649],{"trials":1672,"activeCount":96},[],{"intervention":1674,"totalTrials":92,"cells":1675},"5-aminosalicylate",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1682,"PHASE4":1684,"NA":1697},{"trials":1677,"activeCount":96},[],{"trials":1679,"activeCount":96},[],{"trials":1681,"activeCount":96},[],{"trials":1683,"activeCount":96},[],{"trials":1685,"activeCount":96},[1686],{"nctId":1687,"briefTitle":1688,"status":599,"phases":1689,"completion":1690,"start":1691,"enrollment":627,"conditions":1692,"interventions":1696},"NCT00167882","The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels",[88],"2006-08","2005-07",[1693,1694,1695],"Crohn's Disease","Ulcerative Colitis","Inflammatory Bowel Disease",[1674],{"trials":1698,"activeCount":96},[],{"intervention":1700,"totalTrials":92,"cells":1701},"Natalizumab",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1710,"NA":1722},{"trials":1703,"activeCount":96},[],{"trials":1705,"activeCount":96},[],{"trials":1707,"activeCount":96},[],{"trials":1709,"activeCount":96},[],{"trials":1711,"activeCount":96},[1712],{"nctId":1713,"briefTitle":1714,"status":599,"phases":1715,"primaryCompletion":1716,"completion":1717,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1721},"NCT03516526","Towards Personalized Dosing of Natalizumab in Multiple Sclerosis",[88],"2019-06-21","2019-07-01","2016-11-03",61,[15],[1700],{"trials":1723,"activeCount":96},[],{"intervention":1725,"totalTrials":92,"cells":1726},"Ocrelizumab",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1747},{"trials":1728,"activeCount":96},[],{"trials":1730,"activeCount":96},[],{"trials":1732,"activeCount":96},[],{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[1737],{"nctId":1738,"briefTitle":1739,"status":717,"phases":1740,"primaryCompletion":1741,"completion":1742,"start":1743,"enrollment":1744,"conditions":1745,"interventions":1746},"NCT05296161","B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis",[88],"2024-04","2026-03","2022-04-20",296,[237],[1725],{"trials":1748,"activeCount":96},[],{"intervention":1750,"totalTrials":92,"cells":1751},"Radium-223 chloride",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1771,"NA":1773},{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[1760],{"nctId":1761,"briefTitle":1762,"status":717,"phases":1763,"primaryCompletion":304,"completion":1764,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1769},"NCT03458559","Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy",[87],"2024-05-16","2018-05-16",402,[1768],"Prostate Cancer Metastatic to Bone",[1750,1770],"Rhenium-188-HEDP",{"trials":1772,"activeCount":96},[],{"trials":1774,"activeCount":96},[],{"intervention":1770,"totalTrials":92,"cells":1776},{"EARLY_PHASE1":1777,"PHASE1":1779,"PHASE2":1781,"PHASE3":1783,"PHASE4":1789,"NA":1791},{"trials":1778,"activeCount":96},[],{"trials":1780,"activeCount":96},[],{"trials":1782,"activeCount":96},[],{"trials":1784,"activeCount":96},[1785],{"nctId":1761,"briefTitle":1762,"status":717,"phases":1786,"primaryCompletion":304,"completion":1764,"start":1765,"enrollment":1766,"conditions":1787,"interventions":1788},[87],[1768],[1750,1770],{"trials":1790,"activeCount":96},[],{"trials":1792,"activeCount":96},[],{"intervention":1794,"totalTrials":92,"cells":1795},"Clemastine Fumarate",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1814,"NA":1816},{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[1804],{"nctId":1805,"briefTitle":1806,"status":691,"phases":1807,"primaryCompletion":1808,"completion":1808,"start":1809,"enrollment":1810,"conditions":1811,"interventions":1813},"NCT05338450","Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis",[87],"2025-08-15","2022-08-30",47,[15,1812],"Internuclear Ophthalmoplegia",[1794],{"trials":1815,"activeCount":96},[],{"trials":1817,"activeCount":96},[],{"intervention":1819,"totalTrials":92,"cells":1820},"Sunitinib Malate",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1840,"NA":1842},{"trials":1822,"activeCount":96},[],{"trials":1824,"activeCount":96},[],{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[1829],{"nctId":1830,"briefTitle":1831,"status":717,"phases":1832,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":355,"conditions":1836,"interventions":1838},"NCT03909724","Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)",[86,87],"2021-07-01","2022-07-01","2019-10-01",[28,1837],"Metastasis",[1819,1839],"TAS 102",{"trials":1841,"activeCount":96},[],{"trials":1843,"activeCount":96},[],{"intervention":1839,"totalTrials":92,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1858,"NA":1860},{"trials":1847,"activeCount":96},[],{"trials":1849,"activeCount":96},[],{"trials":1851,"activeCount":96},[],{"trials":1853,"activeCount":96},[1854],{"nctId":1830,"briefTitle":1831,"status":717,"phases":1855,"primaryCompletion":1833,"completion":1834,"start":1835,"enrollment":355,"conditions":1856,"interventions":1857},[86,87],[28,1837],[1819,1839],{"trials":1859,"activeCount":96},[],{"trials":1861,"activeCount":96},[],{"intervention":1863,"totalTrials":92,"cells":1864},"Galantamine",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1871,"PHASE4":1885,"NA":1887},{"trials":1866,"activeCount":96},[],{"trials":1868,"activeCount":96},[],{"trials":1870,"activeCount":96},[],{"trials":1872,"activeCount":96},[1873],{"nctId":1874,"briefTitle":1875,"status":717,"phases":1876,"primaryCompletion":1877,"completion":742,"start":1878,"enrollment":720,"conditions":1879,"interventions":1883},"NCT02098824","Symptomatic Treatment of Vascular Cognitive Impairment",[86,87],"2016-12","2014-02",[1880,1881,1882],"Mild Cognitive Impairment (Vascular)","Mild Cognitive Disorder (Vascular)","Vascular Dementia",[1863,1884],"Methylphenidate",{"trials":1886,"activeCount":96},[],{"trials":1888,"activeCount":96},[],{"intervention":1884,"totalTrials":92,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1897,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":96},[],{"trials":1894,"activeCount":96},[],{"trials":1896,"activeCount":96},[],{"trials":1898,"activeCount":96},[1899],{"nctId":1874,"briefTitle":1875,"status":717,"phases":1900,"primaryCompletion":1877,"completion":742,"start":1878,"enrollment":720,"conditions":1901,"interventions":1902},[86,87],[1880,1881,1882],[1863,1884],{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[],{"intervention":1908,"totalTrials":92,"cells":1909},"Lomustine",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1932,"NA":1934},{"trials":1911,"activeCount":96},[],{"trials":1913,"activeCount":96},[],{"trials":1915,"activeCount":96},[],{"trials":1917,"activeCount":96},[1918],{"nctId":1919,"briefTitle":1920,"status":717,"phases":1921,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":745,"conditions":1924,"interventions":1930},"NCT03025893","A Phase II\u002FIII Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme",[86,87],"2022-01-01","2018-08-31",[1925,1926,1927,1928,1929],"Glioblastoma Multiforme","Glioblastoma, Adult","Glioblastoma","Recurrent Brain Tumor","GBM",[1931,1908],"Sunitinib",{"trials":1933,"activeCount":96},[],{"trials":1935,"activeCount":96},[],{"intervention":1937,"totalTrials":92,"cells":1938},"metoclopramide",{"EARLY_PHASE1":1939,"PHASE1":1941,"PHASE2":1943,"PHASE3":1945,"PHASE4":1959,"NA":1961},{"trials":1940,"activeCount":96},[],{"trials":1942,"activeCount":96},[],{"trials":1944,"activeCount":96},[],{"trials":1946,"activeCount":96},[1947],{"nctId":1948,"briefTitle":1949,"status":599,"phases":1950,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT02135510","MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy",[87],"2019-03-01","2013-06",249,[1955],"Solid Tumors",[1937,1957,1958],"dexamethason","palonosetron",{"trials":1960,"activeCount":96},[],{"trials":1962,"activeCount":96},[],{"intervention":1957,"totalTrials":92,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1971,"PHASE4":1977,"NA":1979},{"trials":1966,"activeCount":96},[],{"trials":1968,"activeCount":96},[],{"trials":1970,"activeCount":96},[],{"trials":1972,"activeCount":96},[1973],{"nctId":1948,"briefTitle":1949,"status":599,"phases":1974,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1975,"interventions":1976},[87],[1955],[1937,1957,1958],{"trials":1978,"activeCount":96},[],{"trials":1980,"activeCount":96},[],{"intervention":1958,"totalTrials":92,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1995,"NA":1997},{"trials":1984,"activeCount":96},[],{"trials":1986,"activeCount":96},[],{"trials":1988,"activeCount":96},[],{"trials":1990,"activeCount":96},[1991],{"nctId":1948,"briefTitle":1949,"status":599,"phases":1992,"primaryCompletion":1951,"completion":1951,"start":1952,"enrollment":1953,"conditions":1993,"interventions":1994},[87],[1955],[1937,1957,1958],{"trials":1996,"activeCount":96},[],{"trials":1998,"activeCount":96},[],{"intervention":2000,"totalTrials":92,"cells":2001},"Rosiglitazone",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2018,"NA":2020},{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":96},[],{"trials":2007,"activeCount":96},[],{"trials":2009,"activeCount":96},[2010],{"nctId":2011,"briefTitle":2012,"status":717,"phases":2013,"completion":2014,"start":2015,"enrollment":720,"conditions":2016,"interventions":2017},"NCT00409097","Effect of Rosiglitazone on ADMA in Critical Illness",[87],"2007-12","2006-04",[32,1642],[2000],{"trials":2019,"activeCount":96},[],{"trials":2021,"activeCount":96},[],{"intervention":2023,"totalTrials":92,"cells":2024},"capecitabine",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2044,"NA":2046},{"trials":2026,"activeCount":96},[],{"trials":2028,"activeCount":96},[],{"trials":2030,"activeCount":96},[],{"trials":2032,"activeCount":96},[2033],{"nctId":2034,"briefTitle":2035,"status":717,"phases":2036,"primaryCompletion":2037,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2043},"NCT02371304","Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers",[87],"2022-06","2023-01","2015-10",302,[2042],"Rectal Cancer",[2023],{"trials":2045,"activeCount":96},[],{"trials":2047,"activeCount":96},[],{"intervention":2049,"totalTrials":92,"cells":2050},"Gefitinib standard dose",{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2052,"activeCount":96},[],{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":96},[2057],{"nctId":2058,"briefTitle":2059,"status":691,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":2063,"enrollment":11,"conditions":2064,"interventions":2066},"NCT02025218","Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients",[86],"2017-01","2017-06","2014-01",[2065],"Lung Cancer",[2049],{"trials":2068,"activeCount":96},[],{"trials":2070,"activeCount":96},[],{"trials":2072,"activeCount":96},[],{"intervention":2074,"totalTrials":92,"cells":2075},"nivolumab-daratumumab",{"EARLY_PHASE1":2076,"PHASE1":2078,"PHASE2":2080,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2077,"activeCount":96},[],{"trials":2079,"activeCount":96},[],{"trials":2081,"activeCount":96},[2082],{"nctId":2083,"briefTitle":2084,"status":599,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2092},"NCT03184194","Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide",[86],"2023-01-25","2024-01-25","2018-02-21",62,[2091],"Myeloma",[2074,2093],"nivolumab-daratumumab with low-dose cyclophosphamide",{"trials":2095,"activeCount":96},[],{"trials":2097,"activeCount":96},[],{"trials":2099,"activeCount":96},[],{"intervention":2093,"totalTrials":92,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2106,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2103,"activeCount":96},[],{"trials":2105,"activeCount":96},[],{"trials":2107,"activeCount":96},[2108],{"nctId":2083,"briefTitle":2084,"status":599,"phases":2109,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2110,"interventions":2111},[86],[2091],[2074,2093],{"trials":2113,"activeCount":96},[],{"trials":2115,"activeCount":96},[],{"trials":2117,"activeCount":96},[],{"intervention":2119,"totalTrials":92,"cells":2120},"Paclitaxel-trastzumab",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2122,"activeCount":96},[],{"trials":2124,"activeCount":96},[],{"trials":2126,"activeCount":96},[2127],{"nctId":2128,"briefTitle":2129,"status":717,"phases":2130,"primaryCompletion":2131,"start":2132,"enrollment":2133,"conditions":2134,"interventions":2137},"NCT02226757","Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients",[86],"2016-08","2014-08",16,[467,2135,2136],"HER2-expression","EGFR-mutation",[2119],{"trials":2139,"activeCount":96},[],{"trials":2141,"activeCount":96},[],{"trials":2143,"activeCount":96},[],{"intervention":2145,"totalTrials":92,"cells":2146},"Panitumumab",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2148,"activeCount":96},[],{"trials":2150,"activeCount":96},[],{"trials":2152,"activeCount":96},[2153],{"nctId":2154,"briefTitle":2155,"status":599,"phases":2156,"primaryCompletion":2157,"completion":1596,"start":2158,"enrollment":9,"conditions":2159,"interventions":2161},"NCT01175733","Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer",[85,86],"2016-03","2010-07-08",[2160],"Pancreatic Cancer",[2145],{"trials":2163,"activeCount":96},[],{"trials":2165,"activeCount":96},[],{"trials":2167,"activeCount":96},[],{"intervention":2169,"totalTrials":92,"cells":2170},"AZD0530 Difumarate",{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2186,"PHASE4":2188,"NA":2190},{"trials":2172,"activeCount":96},[],{"trials":2174,"activeCount":96},[],{"trials":2176,"activeCount":96},[2177],{"nctId":2178,"briefTitle":2179,"status":717,"phases":2180,"primaryCompletion":2181,"completion":2181,"start":2182,"enrollment":109,"conditions":2183,"interventions":2185},"NCT04307953","Saracatinib Trial TO Prevent FOP",[86],"2025-05-06","2020-08-05",[2184],"Fibrodysplasia Ossificans Progressiva",[2169],{"trials":2187,"activeCount":96},[],{"trials":2189,"activeCount":96},[],{"trials":2191,"activeCount":96},[],{"intervention":2193,"totalTrials":92,"cells":2194},"Fluticasone propionate",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2211,"PHASE4":2213,"NA":2215},{"trials":2196,"activeCount":96},[],{"trials":2198,"activeCount":96},[],{"trials":2200,"activeCount":96},[2201],{"nctId":2202,"briefTitle":2203,"status":599,"phases":2204,"completion":2205,"start":2206,"enrollment":2207,"conditions":2208,"interventions":2210},"NCT00407264","Randomized Trial of Fluticasone in Bronchial Premalignancy",[86],"2005-12","2002-02",90,[2209],"Bronchogenic Carcinoma",[2193],{"trials":2212,"activeCount":96},[],{"trials":2214,"activeCount":96},[],{"trials":2216,"activeCount":96},[],{"intervention":2218,"totalTrials":92,"cells":2219},"89Zirconium-labeled ipilimumab",{"EARLY_PHASE1":2220,"PHASE1":2222,"PHASE2":2224,"PHASE3":2236,"PHASE4":2238,"NA":2240},{"trials":2221,"activeCount":96},[],{"trials":2223,"activeCount":96},[],{"trials":2225,"activeCount":96},[2226],{"nctId":2227,"briefTitle":2228,"status":717,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2235},"NCT03313323","Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma",[86],"2022-02-15","2017-02-16",29,[2234],"Melanoma",[2218],{"trials":2237,"activeCount":96},[],{"trials":2239,"activeCount":96},[],{"trials":2241,"activeCount":96},[],{"intervention":2243,"totalTrials":92,"cells":2244},"Dose escalation cetuximab",{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2261,"PHASE4":2263,"NA":2265},{"trials":2246,"activeCount":96},[],{"trials":2248,"activeCount":96},[],{"trials":2250,"activeCount":96},[2251],{"nctId":2252,"briefTitle":2253,"status":691,"phases":2254,"primaryCompletion":2255,"completion":2255,"start":1064,"enrollment":2256,"conditions":2257,"interventions":2259},"NCT02117466","Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer",[85,86],"2021-01",85,[2258],"Metastatic Colorectal Cancer",[2243,2260],"Standard dose cetuximab",{"trials":2262,"activeCount":96},[],{"trials":2264,"activeCount":96},[],{"trials":2266,"activeCount":96},[],{"intervention":2260,"totalTrials":92,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2279,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":96},[],{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":96},[2275],{"nctId":2252,"briefTitle":2253,"status":691,"phases":2276,"primaryCompletion":2255,"completion":2255,"start":1064,"enrollment":2256,"conditions":2277,"interventions":2278},[85,86],[2258],[2243,2260],{"trials":2280,"activeCount":96},[],{"trials":2282,"activeCount":96},[],{"trials":2284,"activeCount":96},[],{"intervention":2286,"totalTrials":92,"cells":2287},"SABR + pembrolizumab",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2303,"PHASE4":2305,"NA":2307},{"trials":2289,"activeCount":96},[],{"trials":2291,"activeCount":96},[],{"trials":2293,"activeCount":96},[2294],{"nctId":2295,"briefTitle":2296,"status":717,"phases":2297,"primaryCompletion":2298,"completion":2298,"start":2299,"enrollment":109,"conditions":2300,"interventions":2302},"NCT03446911","Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery",[85,86],"2020-05","2018-03",[2301],"NSCLC, Stage I",[2286],{"trials":2304,"activeCount":96},[],{"trials":2306,"activeCount":96},[],{"trials":2308,"activeCount":96},[],{"intervention":2310,"totalTrials":92,"cells":2311},"Bisoprolol",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2313,"activeCount":96},[],{"trials":2315,"activeCount":96},[],{"trials":2317,"activeCount":96},[2318],{"nctId":2319,"briefTitle":2320,"status":717,"phases":2321,"primaryCompletion":2063,"completion":1064,"start":2322,"enrollment":720,"conditions":2323,"interventions":2324},"NCT01246037","Beta-blockers in i-PAH",[85,86],"2011-02",[605],[2310],{"trials":2326,"activeCount":96},[],{"trials":2328,"activeCount":96},[],{"trials":2330,"activeCount":96},[],{"intervention":2332,"totalTrials":92,"cells":2333},"Geranylgeranylacetone",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2335,"activeCount":96},[],{"trials":2337,"activeCount":96},[],{"trials":2339,"activeCount":96},[2340],{"nctId":2341,"briefTitle":2342,"status":599,"phases":2343,"primaryCompletion":2344,"completion":2344,"start":2345,"enrollment":2346,"conditions":2347,"interventions":2349},"NCT05672134","Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction",[86],"2024-08-30","2023-04-26",43,[2348],"Heart Failure With Preserved Ejection Fraction",[2332],{"trials":2351,"activeCount":96},[],{"trials":2353,"activeCount":96},[],{"trials":2355,"activeCount":96},[],{"intervention":2357,"totalTrials":92,"cells":2358},"Vitamin C",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2378,"PHASE4":2380,"NA":2382},{"trials":2360,"activeCount":96},[],{"trials":2362,"activeCount":96},[],{"trials":2364,"activeCount":96},[2365],{"nctId":2366,"briefTitle":2367,"status":599,"phases":2368,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2372,"conditions":2373,"interventions":2375},"NCT03509662","Vitamin C in Post-cardiac Arrest",[86],"2024-02-15","2024-08-29","2019-10-07",270,[2374],"Cardiac Arrest",[2357,2376,2377],"Thiamine","Placebos",{"trials":2379,"activeCount":96},[],{"trials":2381,"activeCount":96},[],{"trials":2383,"activeCount":96},[],{"intervention":2376,"totalTrials":92,"cells":2385},{"EARLY_PHASE1":2386,"PHASE1":2388,"PHASE2":2390,"PHASE3":2396,"PHASE4":2398,"NA":2400},{"trials":2387,"activeCount":96},[],{"trials":2389,"activeCount":96},[],{"trials":2391,"activeCount":96},[2392],{"nctId":2366,"briefTitle":2367,"status":599,"phases":2393,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2372,"conditions":2394,"interventions":2395},[86],[2374],[2357,2376,2377],{"trials":2397,"activeCount":96},[],{"trials":2399,"activeCount":96},[],{"trials":2401,"activeCount":96},[],{"intervention":2377,"totalTrials":92,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2414,"PHASE4":2416,"NA":2418},{"trials":2405,"activeCount":96},[],{"trials":2407,"activeCount":96},[],{"trials":2409,"activeCount":96},[2410],{"nctId":2366,"briefTitle":2367,"status":599,"phases":2411,"primaryCompletion":2369,"completion":2370,"start":2371,"enrollment":2372,"conditions":2412,"interventions":2413},[86],[2374],[2357,2376,2377],{"trials":2415,"activeCount":96},[],{"trials":2417,"activeCount":96},[],{"trials":2419,"activeCount":96},[],{"intervention":2421,"totalTrials":92,"cells":2422},"Mifepristone",{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2424,"activeCount":96},[],{"trials":2426,"activeCount":96},[],{"trials":2428,"activeCount":96},[2429],{"nctId":2430,"briefTitle":2431,"status":599,"phases":2432,"primaryCompletion":2433,"completion":2434,"start":2435,"enrollment":2436,"conditions":2437,"interventions":2440},"NCT05217758","RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma",[86],"2024-08-09","2024-11-12","2021-12-09",158,[2438,2439],"Major Depressive Disorder","Childhood Trauma",[2421],{"trials":2442,"activeCount":96},[],{"trials":2444,"activeCount":96},[],{"trials":2446,"activeCount":96},[],{"intervention":2448,"totalTrials":92,"cells":2449},"all-trans retinoic acid",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2451,"activeCount":96},[],{"trials":2453,"activeCount":96},[],{"trials":2455,"activeCount":96},[2456],{"nctId":2457,"briefTitle":2458,"status":599,"phases":2459,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":355,"conditions":2462,"interventions":2463},"NCT02751255","Daratumumab in Combination With ATRA",[85,86],"2022-10-18","2016-07-06",[357],[2448],{"trials":2465,"activeCount":96},[],{"trials":2467,"activeCount":96},[],{"trials":2469,"activeCount":96},[],{"intervention":2471,"totalTrials":92,"cells":2472},"89Zr-Pembrolizumab",{"EARLY_PHASE1":2473,"PHASE1":2475,"PHASE2":2477,"PHASE3":2488,"PHASE4":2490,"NA":2492},{"trials":2474,"activeCount":96},[],{"trials":2476,"activeCount":96},[],{"trials":2478,"activeCount":96},[2479],{"nctId":2480,"briefTitle":2481,"status":717,"phases":2482,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":978,"conditions":2485,"interventions":2487},"NCT03065764","89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer",[86],"2019-12-01","2017-01-20",[2486],"Non Small Cell Lung Cancer",[2471],{"trials":2489,"activeCount":96},[],{"trials":2491,"activeCount":96},[],{"trials":2493,"activeCount":96},[],{"intervention":2495,"totalTrials":92,"cells":2496},"Afatinib, Osimertinib, Carboplatin and Pemetrexed",{"EARLY_PHASE1":2497,"PHASE1":2499,"PHASE2":2501,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2498,"activeCount":96},[],{"trials":2500,"activeCount":96},[],{"trials":2502,"activeCount":96},[2503],{"nctId":2504,"briefTitle":2505,"status":599,"phases":2506,"primaryCompletion":2507,"completion":2507,"start":2508,"enrollment":33,"conditions":2509,"interventions":2511},"NCT05298176","Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors",[86],"2024-04-01","2022-01-04",[2510],"Non-Small Cell Lung Cancer",[2495],{"trials":2513,"activeCount":96},[],{"trials":2515,"activeCount":96},[],{"trials":2517,"activeCount":96},[],{"intervention":2519,"totalTrials":92,"cells":2520},"Nilotinib",{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2522,"activeCount":96},[],{"trials":2524,"activeCount":96},[],{"trials":2526,"activeCount":96},[2527],{"nctId":2528,"briefTitle":2529,"status":691,"phases":2530,"primaryCompletion":2531,"completion":2532,"start":1430,"enrollment":109,"conditions":2533,"interventions":2535},"NCT01866553","Nilotinib Plus Pegylated Interferon-α2b in CML",[86],"2016-04-08","2016-05-01",[2534],"Chronic Myeloid Leukemia",[2519,2536],"Pegylated interferon α-2b",{"trials":2538,"activeCount":96},[],{"trials":2540,"activeCount":96},[],{"trials":2542,"activeCount":96},[],{"intervention":2536,"totalTrials":92,"cells":2544},{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2546,"activeCount":96},[],{"trials":2548,"activeCount":96},[],{"trials":2550,"activeCount":96},[2551],{"nctId":2528,"briefTitle":2529,"status":691,"phases":2552,"primaryCompletion":2531,"completion":2532,"start":1430,"enrollment":109,"conditions":2553,"interventions":2554},[86],[2534],[2519,2536],{"trials":2556,"activeCount":96},[],{"trials":2558,"activeCount":96},[],{"trials":2560,"activeCount":96},[],{"intervention":2562,"totalTrials":179,"cells":2563},"Nivolumab",{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2589,"PHASE3":2591,"PHASE4":2593,"NA":2595},{"trials":2565,"activeCount":96},[],{"trials":2567,"activeCount":96},[2568,2579],{"nctId":2569,"briefTitle":2570,"status":717,"phases":2571,"primaryCompletion":2572,"completion":2573,"start":2574,"enrollment":2575,"conditions":2576,"interventions":2578},"NCT03843515","Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET\u002FCT Imaging for Response Prediction",[85],"2021-11-30","2022-08-31","2019-04-11",17,[2577],"Oral Cavity Squamous Cell Carcinoma",[2562],{"nctId":2580,"briefTitle":2581,"status":717,"phases":2582,"primaryCompletion":2583,"completion":554,"start":2584,"enrollment":9,"conditions":2585,"interventions":2587},"NCT04612530","PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer",[85],"2023-04-01","2020-09-01",[2160,2586],"Metastatic Pancreatic Cancer",[2562,2588],"Toll-Like Receptor 9",{"trials":2590,"activeCount":96},[],{"trials":2592,"activeCount":96},[],{"trials":2594,"activeCount":96},[],{"trials":2596,"activeCount":96},[],{"intervention":2598,"totalTrials":179,"cells":2599},"Bevacizumab",{"EARLY_PHASE1":2600,"PHASE1":2611,"PHASE2":2623,"PHASE3":2625,"PHASE4":2627,"NA":2629},{"trials":2601,"activeCount":96},[2602],{"nctId":2603,"briefTitle":2604,"status":717,"phases":2605,"primaryCompletion":2606,"completion":2607,"start":1878,"enrollment":664,"conditions":2608,"interventions":2610},"NCT02072720","Angiogenic Factor Expression During Fractionated Irradiation",[84],"2021-03","2021-05-01",[2609],"Primary Esophageal Carcinoma",[2598],{"trials":2612,"activeCount":96},[2613],{"nctId":2614,"briefTitle":2615,"status":691,"phases":2616,"primaryCompletion":2617,"completion":2617,"start":2618,"enrollment":24,"conditions":2619,"interventions":2621},"NCT00531076","Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer",[85],"2010-01","2007-10",[2620],"Toxicity",[2622],"bevacizumab",{"trials":2624,"activeCount":96},[],{"trials":2626,"activeCount":96},[],{"trials":2628,"activeCount":96},[],{"trials":2630,"activeCount":96},[],{"intervention":2632,"totalTrials":92,"cells":2633},"GVAX and ipilimumab",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2648,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2635,"activeCount":96},[],{"trials":2637,"activeCount":96},[2638],{"nctId":2639,"briefTitle":2640,"status":691,"phases":2641,"primaryCompletion":2014,"completion":2642,"start":2643,"enrollment":2644,"conditions":2645,"interventions":2647},"NCT01510288","Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer",[85],"2011-11","2004-11",28,[2646],"Prostate Cancer",[2632],{"trials":2649,"activeCount":96},[],{"trials":2651,"activeCount":96},[],{"trials":2653,"activeCount":96},[],{"trials":2655,"activeCount":96},[],{"intervention":2657,"totalTrials":92,"cells":2658},"hVEGF26-104\u002FRFASE",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2672,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2660,"activeCount":96},[],{"trials":2662,"activeCount":96},[2663],{"nctId":2664,"briefTitle":2665,"status":599,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":1064,"enrollment":720,"conditions":2669,"interventions":2671},"NCT02237638","Phase I Study on VEGF Vaccination in Metastatic Solid Tumors",[85],"2020-01","2020-01-01",[2670],"Metastatic Cancer",[2657],{"trials":2673,"activeCount":96},[],{"trials":2675,"activeCount":96},[],{"trials":2677,"activeCount":96},[],{"trials":2679,"activeCount":96},[],{"intervention":2681,"totalTrials":92,"cells":2682},"Cripec Docetaxel",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2684,"activeCount":96},[],{"trials":2686,"activeCount":96},[2687],{"nctId":2688,"briefTitle":2689,"status":599,"phases":2690,"primaryCompletion":1039,"completion":2691,"start":2692,"enrollment":19,"conditions":2693,"interventions":2695},"NCT03712423","PET Study With [89Zr]-Df-CriPec® Docetaxel",[85],"2020-05-08","2018-04-01",[2694],"Solid Tumor",[2681],{"trials":2697,"activeCount":96},[],{"trials":2699,"activeCount":96},[],{"trials":2701,"activeCount":96},[],{"trials":2703,"activeCount":96},[],{"intervention":2588,"totalTrials":92,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2714,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2707,"activeCount":96},[],{"trials":2709,"activeCount":96},[2710],{"nctId":2580,"briefTitle":2581,"status":717,"phases":2711,"primaryCompletion":2583,"completion":554,"start":2584,"enrollment":9,"conditions":2712,"interventions":2713},[85],[2160,2586],[2562,2588],{"trials":2715,"activeCount":96},[],{"trials":2717,"activeCount":96},[],{"trials":2719,"activeCount":96},[],{"trials":2721,"activeCount":96},[],{"intervention":1931,"totalTrials":33,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2737,"PHASE3":2748,"PHASE4":2754,"NA":2756},{"trials":2725,"activeCount":96},[],{"trials":2727,"activeCount":96},[2728],{"nctId":2729,"briefTitle":2730,"status":599,"phases":2731,"primaryCompletion":2732,"completion":2732,"start":2733,"enrollment":2734,"conditions":2735,"interventions":2736},"NCT02058901","Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.",[85],"2019-06","2013-07",101,[1955],[1931],{"trials":2738,"activeCount":96},[2739],{"nctId":2740,"briefTitle":2741,"status":691,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":33,"conditions":2745,"interventions":2747},"NCT02071641","Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma",[86],"2016-09","2012-10",[2746],"Metastatic Renal Cell Carcinoma",[1931],{"trials":2749,"activeCount":96},[2750],{"nctId":1919,"briefTitle":1920,"status":717,"phases":2751,"primaryCompletion":1922,"completion":1922,"start":1923,"enrollment":745,"conditions":2752,"interventions":2753},[86,87],[1925,1926,1927,1928,1929],[1931,1908],{"trials":2755,"activeCount":96},[],{"trials":2757,"activeCount":96},[2758,2775],{"nctId":2759,"briefTitle":2760,"status":599,"phases":2761,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":2764,"interventions":2767},"NCT01636908","Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.",[89],"2018-01-01","2011-08",[2765,2766],"Cancer","Advanced Solid Tumors",[1931,2768,2769,2770,2771,2772,2773,2774],"Sorafenib","Erlotinib","Everolimus","Lapatinib","Dasatinib","Pazopanib","Vemurafenib",{"nctId":2776,"briefTitle":2777,"status":717,"phases":2778,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":505,"conditions":2781,"interventions":2783},"NCT02239952","HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)",[89],"2021-11","2014-11",[2765,2782],"High-grade Glioma",[1931,2784,2769],"vandetanib",{"intervention":1044,"totalTrials":33,"cells":2786},{"EARLY_PHASE1":2787,"PHASE1":2789,"PHASE2":2791,"PHASE3":2793,"PHASE4":2803,"NA":2817},{"trials":2788,"activeCount":96},[],{"trials":2790,"activeCount":96},[],{"trials":2792,"activeCount":96},[],{"trials":2794,"activeCount":96},[2795],{"nctId":2796,"briefTitle":2797,"status":717,"phases":2798,"start":2799,"enrollment":664,"conditions":2800,"interventions":2802},"NCT01254123","Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)",[87],"2009-11",[2801],"Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).",[1044],{"trials":2804,"activeCount":96},[2805,2809,2813],{"nctId":1035,"briefTitle":1036,"status":599,"phases":2806,"primaryCompletion":1038,"completion":1039,"start":1040,"enrollment":1041,"conditions":2807,"interventions":2808},[88],[666,30],[1022,1044],{"nctId":1295,"briefTitle":1296,"status":599,"phases":2810,"primaryCompletion":1298,"completion":1298,"start":1299,"enrollment":1300,"conditions":2811,"interventions":2812},[88],[666,1302],[1304,1282],{"nctId":1426,"briefTitle":1427,"status":599,"phases":2814,"primaryCompletion":1429,"completion":1429,"start":1430,"enrollment":1431,"conditions":2815,"interventions":2816},[88],[26],[1413,1434,1044,1435,1436,1437,1438],{"trials":2818,"activeCount":96},[2819],{"nctId":2820,"briefTitle":2821,"status":599,"phases":2822,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":1370,"conditions":2825,"interventions":2826},"NCT01281228","The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes",[89],"2013-10","2011-09",[655,23,30],[1304,2827],"exenatide + exendin",{"intervention":2769,"totalTrials":588,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2843,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2831,"activeCount":96},[],{"trials":2833,"activeCount":96},[2834],{"nctId":2835,"briefTitle":2836,"status":599,"phases":2837,"primaryCompletion":2014,"completion":2014,"start":2838,"enrollment":16,"conditions":2839,"interventions":2841},"NCT00536861","Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer",[85],"2006-05",[2510,2840],"Brain Metastases",[2842],"erlotinib",{"trials":2844,"activeCount":96},[],{"trials":2846,"activeCount":96},[],{"trials":2848,"activeCount":96},[],{"trials":2850,"activeCount":96},[2851,2855],{"nctId":2759,"briefTitle":2760,"status":599,"phases":2852,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":2853,"interventions":2854},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"nctId":2776,"briefTitle":2777,"status":717,"phases":2856,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":505,"conditions":2857,"interventions":2858},[89],[2765,2782],[1931,2784,2769],{"intervention":2860,"totalTrials":179,"cells":2861},"Dexamethasone",{"EARLY_PHASE1":2862,"PHASE1":2864,"PHASE2":2866,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2863,"activeCount":96},[],{"trials":2865,"activeCount":96},[],{"trials":2867,"activeCount":96},[],{"trials":2869,"activeCount":96},[],{"trials":2871,"activeCount":96},[],{"trials":2873,"activeCount":96},[2874,2882],{"nctId":2875,"briefTitle":2876,"status":691,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":33,"conditions":2880,"interventions":2881},"NCT04128774","Function and Composition of Regulatory B Cells in Participants With Glioblastoma",[],"2024-11-20","2021-01-01",[1926],[2860],{"nctId":2883,"briefTitle":2884,"status":614,"phases":2885,"primaryCompletion":2886,"completion":2887,"start":2888,"enrollment":96,"conditions":2889,"interventions":2892},"NCT00807521","Steroid-induced Reduction of Surgical Stress Study",[89],"2010-12","2011-06","2008-12",[2890,2891],"Coronary Artery Stenosis","Coronary Artery Bypass Graft Surgery",[2860],{"intervention":2772,"totalTrials":179,"cells":2894},{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2896,"activeCount":96},[],{"trials":2898,"activeCount":96},[],{"trials":2900,"activeCount":96},[2901],{"nctId":2902,"briefTitle":2903,"status":717,"phases":2904,"primaryCompletion":2905,"completion":2906,"start":2907,"enrollment":2908,"conditions":2909,"interventions":2911},"NCT03573596","Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment",[86],"2023-02-01","2024-02-01","2018-02-01",134,[2910],"CML, Relapsed",[2772],{"trials":2913,"activeCount":96},[],{"trials":2915,"activeCount":96},[],{"trials":2917,"activeCount":96},[2918],{"nctId":2759,"briefTitle":2760,"status":599,"phases":2919,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":2920,"interventions":2921},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":2768,"totalTrials":179,"cells":2923},{"EARLY_PHASE1":2924,"PHASE1":2926,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2944},{"trials":2925,"activeCount":96},[],{"trials":2927,"activeCount":96},[2928],{"nctId":2929,"briefTitle":2930,"status":599,"phases":2931,"primaryCompletion":2932,"completion":2932,"start":2933,"enrollment":2575,"conditions":2934,"interventions":2936},"NCT02636426","Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study",[85],"2017-12-27","2015-09",[2935],"Neoplasms",[2937],"sorafenib",{"trials":2939,"activeCount":96},[],{"trials":2941,"activeCount":96},[],{"trials":2943,"activeCount":96},[],{"trials":2945,"activeCount":96},[2946],{"nctId":2759,"briefTitle":2760,"status":599,"phases":2947,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":2948,"interventions":2949},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":2951,"totalTrials":179,"cells":2952},"Prednisolone",{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2959,"PHASE4":2961,"NA":2972},{"trials":2954,"activeCount":96},[],{"trials":2956,"activeCount":96},[],{"trials":2958,"activeCount":96},[],{"trials":2960,"activeCount":96},[],{"trials":2962,"activeCount":96},[2963],{"nctId":2964,"briefTitle":2965,"status":599,"phases":2966,"primaryCompletion":1548,"completion":1548,"start":2967,"enrollment":2968,"conditions":2969,"interventions":2971},"NCT02585258","The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study",[88],"2016-06-30",451,[2970],"RheumatoId Arthritis",[2951],{"trials":2973,"activeCount":96},[2974],{"nctId":2975,"briefTitle":2976,"status":599,"phases":2977,"primaryCompletion":2617,"completion":2617,"start":2978,"enrollment":603,"conditions":2979,"interventions":2982},"NCT00744224","PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide",[89],"2009-02",[2980,2981],"Glucocorticoid-induced Glucometabolic Abnormalities","Glucocorticoid-induced Beta-cell Dysfunction",[2951,2983],"Prednisolone and Exenatide",{"intervention":2985,"totalTrials":179,"cells":2986},"Haloperidol",{"EARLY_PHASE1":2987,"PHASE1":2989,"PHASE2":2991,"PHASE3":2993,"PHASE4":2995,"NA":3007},{"trials":2988,"activeCount":96},[],{"trials":2990,"activeCount":96},[],{"trials":2992,"activeCount":96},[],{"trials":2994,"activeCount":96},[],{"trials":2996,"activeCount":96},[2997],{"nctId":2998,"briefTitle":2999,"status":599,"phases":3000,"primaryCompletion":3001,"completion":2039,"start":3002,"enrollment":3003,"conditions":3004,"interventions":3006},"NCT01530308","Haloperidol Prophylaxis in Older Emergency Department Patients",[88],"2015-04","2012-11",242,[3005],"Delirium",[2985],{"trials":3008,"activeCount":96},[3009],{"nctId":3010,"briefTitle":3011,"status":599,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":2734,"conditions":3015,"interventions":3017},"NCT01539733","Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer",[89],"2017-04","2010-03",[3005,3016],"Advanced Cancer",[3018,2985],"Olanzapine",{"intervention":3020,"totalTrials":92,"cells":3021},"Insulin detemir",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":96},[],{"trials":3025,"activeCount":96},[],{"trials":3027,"activeCount":96},[],{"trials":3029,"activeCount":96},[],{"trials":3031,"activeCount":96},[],{"trials":3033,"activeCount":96},[3034],{"nctId":3035,"briefTitle":3036,"status":599,"phases":3037,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":664,"conditions":3040,"interventions":3042},"NCT00626080","Insulin Detemir Action in Cerebro",[89],"2011-12","2009-01",[3041],"Type 1 Diabetes",[3020,3043],"Insulin NPH",{"intervention":3043,"totalTrials":92,"cells":3045},{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3047,"activeCount":96},[],{"trials":3049,"activeCount":96},[],{"trials":3051,"activeCount":96},[],{"trials":3053,"activeCount":96},[],{"trials":3055,"activeCount":96},[],{"trials":3057,"activeCount":96},[3058],{"nctId":3035,"briefTitle":3036,"status":599,"phases":3059,"primaryCompletion":3038,"completion":3038,"start":3039,"enrollment":664,"conditions":3060,"interventions":3061},[89],[3041],[3020,3043],{"intervention":3063,"totalTrials":92,"cells":3064},"Treatment: additional albumin during cardiopulmonary bypass",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3066,"activeCount":96},[],{"trials":3068,"activeCount":96},[],{"trials":3070,"activeCount":96},[],{"trials":3072,"activeCount":96},[],{"trials":3074,"activeCount":96},[],{"trials":3076,"activeCount":96},[3077],{"nctId":3078,"briefTitle":3079,"status":717,"phases":3080,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3085,"interventions":3089},"NCT05647200","Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass, Part II",[89],"2024-07-15","2025-01-15","2023-10-15",64,[3086,3087,3088],"Endothelial Dysfunction","Hemolysis","Fluid Overload",[3063,3090],"control: additional ringers during cardiopulmonary bypass",{"intervention":3090,"totalTrials":92,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3094,"activeCount":96},[],{"trials":3096,"activeCount":96},[],{"trials":3098,"activeCount":96},[],{"trials":3100,"activeCount":96},[],{"trials":3102,"activeCount":96},[],{"trials":3104,"activeCount":96},[3105],{"nctId":3078,"briefTitle":3079,"status":717,"phases":3106,"primaryCompletion":3081,"completion":3082,"start":3083,"enrollment":3084,"conditions":3107,"interventions":3108},[89],[3086,3087,3088],[3063,3090],{"intervention":2827,"totalTrials":92,"cells":3110},{"EARLY_PHASE1":3111,"PHASE1":3113,"PHASE2":3115,"PHASE3":3117,"PHASE4":3119,"NA":3121},{"trials":3112,"activeCount":96},[],{"trials":3114,"activeCount":96},[],{"trials":3116,"activeCount":96},[],{"trials":3118,"activeCount":96},[],{"trials":3120,"activeCount":96},[],{"trials":3122,"activeCount":96},[3123],{"nctId":2820,"briefTitle":2821,"status":599,"phases":3124,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":1370,"conditions":3125,"interventions":3126},[89],[655,23,30],[1304,2827],{"intervention":3128,"totalTrials":92,"cells":3129},"methylnaltrexone",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3138,"NA":3140},{"trials":3131,"activeCount":96},[],{"trials":3133,"activeCount":96},[],{"trials":3135,"activeCount":96},[],{"trials":3137,"activeCount":96},[],{"trials":3139,"activeCount":96},[],{"trials":3141,"activeCount":96},[3142],{"nctId":3143,"briefTitle":3144,"status":691,"phases":3145,"primaryCompletion":719,"completion":719,"start":3146,"enrollment":19,"conditions":3147,"interventions":3149},"NCT01955213","Methylnaltrexone for Opioid Induced Constipation",[],"2012-07",[3148],"Constipation",[3128],{"intervention":3151,"totalTrials":92,"cells":3152},"DMT",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3163},{"trials":3154,"activeCount":96},[],{"trials":3156,"activeCount":96},[],{"trials":3158,"activeCount":96},[],{"trials":3160,"activeCount":96},[],{"trials":3162,"activeCount":96},[],{"trials":3164,"activeCount":96},[3165],{"nctId":3166,"briefTitle":3167,"status":717,"phases":3168,"primaryCompletion":3169,"completion":3170,"start":617,"enrollment":3171,"conditions":3172,"interventions":3174},"NCT04260711","Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).",[89],"2023-08-01","2024-01-01",130,[15,237,3173],"Multiple Sclerosis, Secondary Progressive",[3151],{"intervention":3176,"totalTrials":92,"cells":3177},"Aliskiren",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3179,"activeCount":96},[],{"trials":3181,"activeCount":96},[],{"trials":3183,"activeCount":96},[],{"trials":3185,"activeCount":96},[],{"trials":3187,"activeCount":96},[],{"trials":3189,"activeCount":96},[3190],{"nctId":3191,"briefTitle":3192,"status":691,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":2824,"enrollment":588,"conditions":3195,"interventions":3197},"NCT01425242","Study on Anti-inflammatory Effect of Anti-hypertensive Treatment in Patients With Small AAA's and Mild Hypertension",[89],"2013-12",[656,3196],"Abdominal Aortic Aneurysm",[3176,3198],"Amlodipine",{"intervention":3198,"totalTrials":92,"cells":3200},{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3207,"PHASE4":3209,"NA":3211},{"trials":3202,"activeCount":96},[],{"trials":3204,"activeCount":96},[],{"trials":3206,"activeCount":96},[],{"trials":3208,"activeCount":96},[],{"trials":3210,"activeCount":96},[],{"trials":3212,"activeCount":96},[3213],{"nctId":3191,"briefTitle":3192,"status":691,"phases":3214,"primaryCompletion":3194,"completion":3194,"start":2824,"enrollment":588,"conditions":3215,"interventions":3216},[89],[656,3196],[3176,3198],{"intervention":2770,"totalTrials":92,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3220,"activeCount":96},[],{"trials":3222,"activeCount":96},[],{"trials":3224,"activeCount":96},[],{"trials":3226,"activeCount":96},[],{"trials":3228,"activeCount":96},[],{"trials":3230,"activeCount":96},[3231],{"nctId":2759,"briefTitle":2760,"status":599,"phases":3232,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":3233,"interventions":3234},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":2771,"totalTrials":92,"cells":3236},{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3238,"activeCount":96},[],{"trials":3240,"activeCount":96},[],{"trials":3242,"activeCount":96},[],{"trials":3244,"activeCount":96},[],{"trials":3246,"activeCount":96},[],{"trials":3248,"activeCount":96},[3249],{"nctId":2759,"briefTitle":2760,"status":599,"phases":3250,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":3251,"interventions":3252},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":2773,"totalTrials":92,"cells":3254},{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3259,"PHASE3":3261,"PHASE4":3263,"NA":3265},{"trials":3256,"activeCount":96},[],{"trials":3258,"activeCount":96},[],{"trials":3260,"activeCount":96},[],{"trials":3262,"activeCount":96},[],{"trials":3264,"activeCount":96},[],{"trials":3266,"activeCount":96},[3267],{"nctId":2759,"briefTitle":2760,"status":599,"phases":3268,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":3269,"interventions":3270},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":2774,"totalTrials":92,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3274,"activeCount":96},[],{"trials":3276,"activeCount":96},[],{"trials":3278,"activeCount":96},[],{"trials":3280,"activeCount":96},[],{"trials":3282,"activeCount":96},[],{"trials":3284,"activeCount":96},[3285],{"nctId":2759,"briefTitle":2760,"status":599,"phases":3286,"primaryCompletion":2762,"completion":2483,"start":2763,"enrollment":2346,"conditions":3287,"interventions":3288},[89],[2765,2766],[1931,2768,2769,2770,2771,2772,2773,2774],{"intervention":3290,"totalTrials":92,"cells":3291},"Dexamfetamine Sulfate 5 Mg Oral",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3298,"PHASE4":3300,"NA":3302},{"trials":3293,"activeCount":96},[],{"trials":3295,"activeCount":96},[],{"trials":3297,"activeCount":96},[],{"trials":3299,"activeCount":96},[],{"trials":3301,"activeCount":96},[],{"trials":3303,"activeCount":96},[3304],{"nctId":3305,"briefTitle":3306,"status":599,"phases":3307,"primaryCompletion":3308,"completion":3309,"start":1833,"enrollment":2133,"conditions":3310,"interventions":3312},"NCT04946461","The Day-time Response Variation of (Lis)Dexamphetamine",[],"2021-12-30","2022-06-16",[3311],"Adhd",[3290,3313,3314],"Lisdexamfetamine Dimesylate","blood samples",{"intervention":3313,"totalTrials":92,"cells":3316},{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3318,"activeCount":96},[],{"trials":3320,"activeCount":96},[],{"trials":3322,"activeCount":96},[],{"trials":3324,"activeCount":96},[],{"trials":3326,"activeCount":96},[],{"trials":3328,"activeCount":96},[3329],{"nctId":3305,"briefTitle":3306,"status":599,"phases":3330,"primaryCompletion":3308,"completion":3309,"start":1833,"enrollment":2133,"conditions":3331,"interventions":3332},[],[3311],[3290,3313,3314],{"intervention":3314,"totalTrials":92,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3336,"activeCount":96},[],{"trials":3338,"activeCount":96},[],{"trials":3340,"activeCount":96},[],{"trials":3342,"activeCount":96},[],{"trials":3344,"activeCount":96},[],{"trials":3346,"activeCount":96},[3347],{"nctId":3305,"briefTitle":3306,"status":599,"phases":3348,"primaryCompletion":3308,"completion":3309,"start":1833,"enrollment":2133,"conditions":3349,"interventions":3350},[],[3311],[3290,3313,3314],{"intervention":3352,"totalTrials":92,"cells":3353},"Iloprost",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3355,"activeCount":96},[],{"trials":3357,"activeCount":96},[],{"trials":3359,"activeCount":96},[],{"trials":3361,"activeCount":96},[],{"trials":3363,"activeCount":96},[],{"trials":3365,"activeCount":96},[3366],{"nctId":3367,"briefTitle":3368,"status":599,"phases":3369,"primaryCompletion":3370,"completion":3370,"start":3371,"enrollment":505,"conditions":3372,"interventions":3374},"NCT03380325","The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes",[89],"2017-06-29","2016-05-11",[23,3373],"Insulin Sensitivity\u002FResistance",[3352],{"intervention":3376,"totalTrials":92,"cells":3377},"Liraglutide treatment 12 weeks",{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3379,"activeCount":96},[],{"trials":3381,"activeCount":96},[],{"trials":3383,"activeCount":96},[],{"trials":3385,"activeCount":96},[],{"trials":3387,"activeCount":96},[],{"trials":3389,"activeCount":96},[3390],{"nctId":3391,"briefTitle":3392,"status":599,"phases":3393,"primaryCompletion":3394,"completion":3394,"start":3395,"enrollment":1094,"conditions":3396,"interventions":3397},"NCT01363609","Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes",[89],"2015-01","2011-10",[30,26],[3376,3398,3399],"insulin glargine treatment","GLP-1 receptor antagonist",{"intervention":3398,"totalTrials":92,"cells":3401},{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3406,"PHASE3":3408,"PHASE4":3410,"NA":3412},{"trials":3403,"activeCount":96},[],{"trials":3405,"activeCount":96},[],{"trials":3407,"activeCount":96},[],{"trials":3409,"activeCount":96},[],{"trials":3411,"activeCount":96},[],{"trials":3413,"activeCount":96},[3414],{"nctId":3391,"briefTitle":3392,"status":599,"phases":3415,"primaryCompletion":3394,"completion":3394,"start":3395,"enrollment":1094,"conditions":3416,"interventions":3417},[89],[30,26],[3376,3398,3399],{"intervention":3399,"totalTrials":92,"cells":3419},{"EARLY_PHASE1":3420,"PHASE1":3422,"PHASE2":3424,"PHASE3":3426,"PHASE4":3428,"NA":3430},{"trials":3421,"activeCount":96},[],{"trials":3423,"activeCount":96},[],{"trials":3425,"activeCount":96},[],{"trials":3427,"activeCount":96},[],{"trials":3429,"activeCount":96},[],{"trials":3431,"activeCount":96},[3432],{"nctId":3391,"briefTitle":3392,"status":599,"phases":3433,"primaryCompletion":3394,"completion":3394,"start":3395,"enrollment":1094,"conditions":3434,"interventions":3435},[89],[30,26],[3376,3398,3399],{"intervention":3437,"totalTrials":92,"cells":3438},"Everolimus plus Exemestane",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3443,"PHASE3":3445,"PHASE4":3447,"NA":3449},{"trials":3440,"activeCount":96},[],{"trials":3442,"activeCount":96},[],{"trials":3444,"activeCount":96},[],{"trials":3446,"activeCount":96},[],{"trials":3448,"activeCount":96},[],{"trials":3450,"activeCount":96},[3451],{"nctId":3452,"briefTitle":3453,"status":717,"phases":3454,"primaryCompletion":2255,"completion":2255,"start":1369,"enrollment":3455,"conditions":3456,"interventions":3459},"NCT02109913","Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane",[89],175,[3457,3458],"Hormone Receptor Positive Malignant Neoplasm of Breast","Metastatic Breast Cancer",[3437],{"intervention":3018,"totalTrials":92,"cells":3461},{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3466,"PHASE3":3468,"PHASE4":3470,"NA":3472},{"trials":3463,"activeCount":96},[],{"trials":3465,"activeCount":96},[],{"trials":3467,"activeCount":96},[],{"trials":3469,"activeCount":96},[],{"trials":3471,"activeCount":96},[],{"trials":3473,"activeCount":96},[3474],{"nctId":3010,"briefTitle":3011,"status":599,"phases":3475,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":2734,"conditions":3476,"interventions":3477},[89],[3005,3016],[3018,2985],{"intervention":3479,"totalTrials":92,"cells":3480},"Modulation of FiO2",{"EARLY_PHASE1":3481,"PHASE1":3483,"PHASE2":3485,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3482,"activeCount":96},[],{"trials":3484,"activeCount":96},[],{"trials":3486,"activeCount":96},[],{"trials":3488,"activeCount":96},[],{"trials":3490,"activeCount":96},[],{"trials":3492,"activeCount":96},[3493],{"nctId":3494,"briefTitle":3495,"status":717,"phases":3496,"primaryCompletion":2668,"completion":3497,"start":3498,"enrollment":109,"conditions":3499,"interventions":3501},"NCT03156218","The Effect of FiO2 on PaO2\u002FFiO2 Ratio",[89],"2020-08-01","2017-09-01",[3500],"PaO2\u002FFiO2 Ratio",[3479],{"intervention":3503,"totalTrials":92,"cells":3504},"A: gelofusine + ringers",{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3511,"PHASE4":3513,"NA":3515},{"trials":3506,"activeCount":96},[],{"trials":3508,"activeCount":96},[],{"trials":3510,"activeCount":96},[],{"trials":3512,"activeCount":96},[],{"trials":3514,"activeCount":96},[],{"trials":3516,"activeCount":96},[3517],{"nctId":3518,"briefTitle":3519,"status":599,"phases":3520,"primaryCompletion":3521,"completion":3522,"start":3523,"enrollment":1370,"conditions":3524,"interventions":3525},"NCT05647057","CPB Prime Fluid Strategies to Preserve Mcirocirculatory Perfusion",[89],"2024-07-08","2024-08-08","2023-07-10",[3086,3087,3088],[3503,3526,3527],"B: albumine + ringers","C: ringers + retrograde autologous priming",{"intervention":3526,"totalTrials":92,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3531,"activeCount":96},[],{"trials":3533,"activeCount":96},[],{"trials":3535,"activeCount":96},[],{"trials":3537,"activeCount":96},[],{"trials":3539,"activeCount":96},[],{"trials":3541,"activeCount":96},[3542],{"nctId":3518,"briefTitle":3519,"status":599,"phases":3543,"primaryCompletion":3521,"completion":3522,"start":3523,"enrollment":1370,"conditions":3544,"interventions":3545},[89],[3086,3087,3088],[3503,3526,3527],{"intervention":3527,"totalTrials":92,"cells":3547},{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3552,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3549,"activeCount":96},[],{"trials":3551,"activeCount":96},[],{"trials":3553,"activeCount":96},[],{"trials":3555,"activeCount":96},[],{"trials":3557,"activeCount":96},[],{"trials":3559,"activeCount":96},[3560],{"nctId":3518,"briefTitle":3519,"status":599,"phases":3561,"primaryCompletion":3521,"completion":3522,"start":3523,"enrollment":1370,"conditions":3562,"interventions":3563},[89],[3086,3087,3088],[3503,3526,3527],{"intervention":3565,"totalTrials":92,"cells":3566},"Ceftriaxone 2000 mg",{"EARLY_PHASE1":3567,"PHASE1":3569,"PHASE2":3571,"PHASE3":3573,"PHASE4":3575,"NA":3577},{"trials":3568,"activeCount":96},[],{"trials":3570,"activeCount":96},[],{"trials":3572,"activeCount":96},[],{"trials":3574,"activeCount":96},[],{"trials":3576,"activeCount":96},[],{"trials":3578,"activeCount":96},[3579],{"nctId":3580,"briefTitle":3581,"status":599,"phases":3582,"primaryCompletion":2062,"completion":2062,"start":3583,"enrollment":3584,"conditions":3585,"interventions":3588},"NCT01988428","Prehospital Antibiotics Against Sepsis Trial",[89],"2014-06",2672,[1643,3586,3587],"Severe Sepsis","Septic Shock",[3565],{"intervention":3590,"totalTrials":92,"cells":3591},"Sitagliptin 100 mg",{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3596,"PHASE3":3598,"PHASE4":3600,"NA":3602},{"trials":3593,"activeCount":96},[],{"trials":3595,"activeCount":96},[],{"trials":3597,"activeCount":96},[],{"trials":3599,"activeCount":96},[],{"trials":3601,"activeCount":96},[],{"trials":3603,"activeCount":96},[3604],{"nctId":3605,"briefTitle":3606,"status":599,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3611,"interventions":3615},"NCT00721552","Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome",[89],"2012-06","2008-10",82,[655,3612,3613,3614],"Steroid Diabetes","Glucocorticoid-induced Diabetes","Beta-cell Function",[3590,3616,3617,3618],"Prednisolone 30 mg","Sitagliptin-placebo","Prednisolone-placebo",{"intervention":3616,"totalTrials":92,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3627,"PHASE4":3629,"NA":3631},{"trials":3622,"activeCount":96},[],{"trials":3624,"activeCount":96},[],{"trials":3626,"activeCount":96},[],{"trials":3628,"activeCount":96},[],{"trials":3630,"activeCount":96},[],{"trials":3632,"activeCount":96},[3633],{"nctId":3605,"briefTitle":3606,"status":599,"phases":3634,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3635,"interventions":3636},[89],[655,3612,3613,3614],[3590,3616,3617,3618],{"intervention":3617,"totalTrials":92,"cells":3638},{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3640,"activeCount":96},[],{"trials":3642,"activeCount":96},[],{"trials":3644,"activeCount":96},[],{"trials":3646,"activeCount":96},[],{"trials":3648,"activeCount":96},[],{"trials":3650,"activeCount":96},[3651],{"nctId":3605,"briefTitle":3606,"status":599,"phases":3652,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3653,"interventions":3654},[89],[655,3612,3613,3614],[3590,3616,3617,3618],{"intervention":3618,"totalTrials":92,"cells":3656},{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3663,"PHASE4":3665,"NA":3667},{"trials":3658,"activeCount":96},[],{"trials":3660,"activeCount":96},[],{"trials":3662,"activeCount":96},[],{"trials":3664,"activeCount":96},[],{"trials":3666,"activeCount":96},[],{"trials":3668,"activeCount":96},[3669],{"nctId":3605,"briefTitle":3606,"status":599,"phases":3670,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":3610,"conditions":3671,"interventions":3672},[89],[655,3612,3613,3614],[3590,3616,3617,3618],{"intervention":3674,"totalTrials":92,"cells":3675},"Vitamin D",{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3682,"PHASE4":3684,"NA":3686},{"trials":3677,"activeCount":96},[],{"trials":3679,"activeCount":96},[],{"trials":3681,"activeCount":96},[],{"trials":3683,"activeCount":96},[],{"trials":3685,"activeCount":96},[],{"trials":3687,"activeCount":96},[3688],{"nctId":3689,"briefTitle":3690,"status":599,"phases":3691,"primaryCompletion":3692,"completion":3692,"start":3693,"enrollment":2436,"conditions":3694,"interventions":3696},"NCT02122627","Vitamin D Supplementation in Patients With COPD",[89],"2019-06-26","2015-04-10",[3695],"Chronic Obstructive Pulmonary Disease",[3674],{"intervention":2983,"totalTrials":92,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3705,"PHASE4":3707,"NA":3709},{"trials":3700,"activeCount":96},[],{"trials":3702,"activeCount":96},[],{"trials":3704,"activeCount":96},[],{"trials":3706,"activeCount":96},[],{"trials":3708,"activeCount":96},[],{"trials":3710,"activeCount":96},[3711],{"nctId":2975,"briefTitle":2976,"status":599,"phases":3712,"primaryCompletion":2617,"completion":2617,"start":2978,"enrollment":603,"conditions":3713,"interventions":3714},[89],[2980,2981],[2951,2983],{"intervention":3716,"totalTrials":92,"cells":3717},"desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3726,"NA":3728},{"trials":3719,"activeCount":96},[],{"trials":3721,"activeCount":96},[],{"trials":3723,"activeCount":96},[],{"trials":3725,"activeCount":96},[],{"trials":3727,"activeCount":96},[],{"trials":3729,"activeCount":96},[3730],{"nctId":3731,"briefTitle":3732,"status":691,"phases":3733,"primaryCompletion":3734,"completion":3734,"start":3735,"enrollment":3736,"conditions":3737,"interventions":3739},"NCT01190241","Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study",[89],"2017-12","2010-08",45,[2766,3738,1837],"Inoperable",[3716],{"intervention":2784,"totalTrials":92,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3743,"activeCount":96},[],{"trials":3745,"activeCount":96},[],{"trials":3747,"activeCount":96},[],{"trials":3749,"activeCount":96},[],{"trials":3751,"activeCount":96},[],{"trials":3753,"activeCount":96},[3754],{"nctId":2776,"briefTitle":2777,"status":717,"phases":3755,"primaryCompletion":2779,"completion":2779,"start":2780,"enrollment":505,"conditions":3756,"interventions":3757},[89],[2765,2782],[1931,2784,2769],{"intervention":3759,"totalTrials":92,"cells":3760},"Volcolon sugar free",{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3765,"PHASE3":3767,"PHASE4":3769,"NA":3771},{"trials":3762,"activeCount":96},[],{"trials":3764,"activeCount":96},[],{"trials":3766,"activeCount":96},[],{"trials":3768,"activeCount":96},[],{"trials":3770,"activeCount":96},[],{"trials":3772,"activeCount":96},[3773],{"nctId":3774,"briefTitle":3775,"status":599,"phases":3776,"primaryCompletion":1877,"completion":1877,"start":1639,"enrollment":745,"conditions":3777,"interventions":3778},"NCT02867917","Comparison of Taste and Palatability in Fiber Supplements",[89],[3148],[3759,3779,3780],"Metamucil Orange","Psyllium Orange",{"intervention":3779,"totalTrials":92,"cells":3782},{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":96},[],{"trials":3786,"activeCount":96},[],{"trials":3788,"activeCount":96},[],{"trials":3790,"activeCount":96},[],{"trials":3792,"activeCount":96},[],{"trials":3794,"activeCount":96},[3795],{"nctId":3774,"briefTitle":3775,"status":599,"phases":3796,"primaryCompletion":1877,"completion":1877,"start":1639,"enrollment":745,"conditions":3797,"interventions":3798},[89],[3148],[3759,3779,3780],{"intervention":3780,"totalTrials":92,"cells":3800},{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3807,"PHASE4":3809,"NA":3811},{"trials":3802,"activeCount":96},[],{"trials":3804,"activeCount":96},[],{"trials":3806,"activeCount":96},[],{"trials":3808,"activeCount":96},[],{"trials":3810,"activeCount":96},[],{"trials":3812,"activeCount":96},[3813],{"nctId":3774,"briefTitle":3775,"status":599,"phases":3814,"primaryCompletion":1877,"completion":1877,"start":1639,"enrollment":745,"conditions":3815,"interventions":3816},[89],[3148],[3759,3779,3780],{"intervention":3818,"totalTrials":92,"cells":3819},"Aminobiphosphonate",{"EARLY_PHASE1":3820,"PHASE1":3822,"PHASE2":3824,"PHASE3":3826,"PHASE4":3828,"NA":3830},{"trials":3821,"activeCount":96},[],{"trials":3823,"activeCount":96},[],{"trials":3825,"activeCount":96},[],{"trials":3827,"activeCount":96},[],{"trials":3829,"activeCount":96},[],{"trials":3831,"activeCount":96},[3832],{"nctId":3833,"briefTitle":3834,"status":599,"phases":3835,"primaryCompletion":694,"completion":694,"start":3735,"enrollment":3836,"conditions":3837,"interventions":3839},"NCT01179464","Effect of Aminobiphosphonates and Statins on Circulating Vgamma9Vdelta2-T Cells",[89],19,[3838],"Bone Metastases of a Malignant Tumor",[3818,3840],"Simvastatin",{"intervention":3840,"totalTrials":92,"cells":3842},{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3849,"PHASE4":3851,"NA":3853},{"trials":3844,"activeCount":96},[],{"trials":3846,"activeCount":96},[],{"trials":3848,"activeCount":96},[],{"trials":3850,"activeCount":96},[],{"trials":3852,"activeCount":96},[],{"trials":3854,"activeCount":96},[3855],{"nctId":3833,"briefTitle":3834,"status":599,"phases":3856,"primaryCompletion":694,"completion":694,"start":3735,"enrollment":3836,"conditions":3857,"interventions":3858},[89],[3838],[3818,3840],{"intervention":3860,"totalTrials":92,"cells":3861},"Indocyanine green",{"EARLY_PHASE1":3862,"PHASE1":3864,"PHASE2":3866,"PHASE3":3868,"PHASE4":3870,"NA":3872},{"trials":3863,"activeCount":96},[],{"trials":3865,"activeCount":96},[],{"trials":3867,"activeCount":96},[],{"trials":3869,"activeCount":96},[],{"trials":3871,"activeCount":96},[],{"trials":3873,"activeCount":96},[3874],{"nctId":3875,"briefTitle":3876,"status":717,"phases":3877,"primaryCompletion":3878,"completion":3878,"start":3879,"enrollment":3880,"conditions":3881,"interventions":3883},"NCT06129669","ICG Indocyanine Green in Reconstructive Surgery",[],"2025-05","2023-05-09",160,[333,3882],"Fluorescence",[3860]]